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Poly(ortho ester) (POE), poly(ortho ester) (POE)-poly (ethylene glycol) (PEG)-
poly(ortho ester) (POE) triblock copolymers (POE-PEG-POE) and POE/PEG polymer 
blends with different PEG contents/molecular weights have been studied as the 
carriers for controlled protein delivery. Polymeric microspheres containing bovine 
serum albumin (BSA) were prepared using a double emulsion (water- in-oil- in-water) 
process.  
 
Firstly, the fundamentals of the fabrication and characterization of POE-PEG-POE 
microspheres are reported. Since triblock copolymer is more hydrophilic than neat 
poly(ortho ester), it yields a more stable first emulsion (water- in-oil) and a greater 
BSA encapsulation efficiency. Uniform BSA distributions are observed within the 
microspheres by a confocal microscope. SEM pictures show that an increase in PEG 
content results in microspheres with a denser cross-section because of a more stable 
first emulsion and better affinity between the copolymer and water. POE-PEG(20%)-
POE suffer significant swelling during the fabrication process and yields the biggest 
microspheres. Salt concentration in the external water phase significantly affects 
morphology of the resultant microspheres. Microspheres with a dense wall are 
produced when using pure water as the external water phase. Polymer concentration 
has less impact on BSA encapsulation efficiency but has a considerable effect on 
microsphere size and morphology. Increasing the concentration of the polyvinyl 
alcohol emulsifier does not cause an obvious decrease in microsphere size. However, 
an increased BSA loading results in bigger microspheres.  
 
vii i 
Following the previous research, the polymer erosion and the mechanism of protein 
release are studied. 14-week in vitro behaviours of POE-PEG-POE microspheres 
loaded with BSA have been monitored. SEM micrographs reveal that after 14-week 
incubation in PBS buffer, pH 7.4, 37ºC, the polymeric particles remain spherical 
despite mass loss of almost 90%. On the other hand, molecular weight undergoes a 
high initial lose during the first two-week incubation for POE-PEG(5%)-POE and 
POE-PEG(10%)-POE. Then, it keeps relatively unchanged over 12 weeks. However, 
POE-PEG(20%)-POE copolymer provides a better compatibility between the POE 
and PEG blocks. Thus, its molecular weight remains relatively constant and mass loss 
shows quite sustained over the 14-week in vitro release. The similar phenomena are 
observed in the polydispersity index of the degrading copolymers. SDS-PAGE of the 
encapsulated BSA within the POE-PEG(5%)-POE microspheres displays that the 
structural integrity of BSA is intact for at least 8 weeks due to a mild environment 
provided by the copolymer. In addition, XPS and FTIR are utilised to investigate 
protein behaviours in the degrading microspheres. Protein release from the POE-PEG-
POE microspheres shows a biphasic pattern, characterised by an initial stage followed 
by a non-detectable release. The non-release phase is dominated by either slow 
polymer degradation or dense microsphere matrix structures. The microsphere 
formulation is optimised and a sustained protein release over two weeks is achieved 
by using POE-PEG(20%)-POE at a high protein loading. 
 
Modulation of BSA release from POE-PEG-POE microspheres has been investigated. 
Effect of PEG molecular weight and POE composition were studied. These results 
show that changing PEG molecular weight has little effect on the BSA release 
properties from POE-PEG-POE microspheres. Micropsheres made from POE-
ix 
PEG(Mn 1,000)-POE microspheres with more flexible POE block are investigated. 
More BSA can release from microspheres while higher initial burst and shorter 
release period (about 5 days) are introduced by this release system. Based on these 
studies, BSA release profiles could be optimised to a three-week nearly linear release. 
 
On the other hand, POE/PEG blends of different PEG molecular weights and weight 
ratios have been utilized to alter the polymer degradation rate and therefore to modify 
the drug release kinetics from microspheres. BSA was encapsulated into POE/PEG 
blend microspheres using the W/O/W double emulsion technique. With the changing 
of PEG molecular weight and weight ratio, morphology, particle size, water uptake 
etc of the microspheres may be changed accordingly. Increasing the initial PEG 
content resulted in changing encapsulation efficiency, depending on the balance 
between polymer solution stability and water penetration. Changes of microspheres 

















Mw    Molecular weight (weight average) 
Mn    Molecular weight (number average) 
 
Abbreviation 
ASF    Atomic sensitivity factors 
BSA    Bovine serum albumin  
CDM    trans-cyclohexanedimethanol  
CLSM    Confocal laser scanning microscope  
cP    Centipoise  
DETUSO   3,9-diethylidene-2,4,8,10-tetraoxaspiro{5,5} undecane  
DSC    Differential scanning calorimetry  
FTIR    Fourier transform infrared spectrophotometer  
GPC    Gel permeation chromatography  
HPSEC   High performance size exclusion chromatography  
PBS    Phosphate buffer solution  
PEG    Poly (ethylene glycol) 
PLGA    Poly(lactic-co-glylic acid)  
POE    Poly(ortho ester) 
PrD    Propanediol 
PTSA    p-toluenesulfonic acid 
PVA    Poly (vinyl alcohol)  
xi 
SDS-PAGE Sodium dodecyl sulpha te-polyacrylamide gel 
electrophoresis 
SEM    Scanning electron microscope 
TEG    Tri(ethylene glycol) 
TEG-diGL   Tri(ethylene glycol)-diglycolide  
THF    Tetrahydrofuran 
Tween 80   Polyoxyethylene-sorbitan monooleate 
UV    Ultraviolet 
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 2 
1.1 Scope of the Research 
 
Successful drug therapy may be achieved in three ways: delivering the drug 
efficiently to the target; modifying the drug for increased efficiency; or finding a 
novel drug of inherently high efficacy. Of these three methods, to devise an efficient 
means of delivery is the most cost-effective one.  
 
Conventional drug delivery systems have not incorporated the means of controlled 
release. The problem, however, is that after each dose, drug concentration 
immediately peaks and then declines rapidly. Taking four doses of a drug each day, 
for example, would yield a drug absorption pattern similar to Curve A of Figure 1.1. 
At times, the drug concentration is higher than the maximum level, leading to side 
effects. At other times, the concentration is too low to provide therapeutic benefits. It 
is desirable to release a drug at a constant rate, thereby maintaining drug level within 
the therapeutic window and reducing or eliminating side effects caused by over 
dosing.  
 
Controlled drug delivery systems serve two functions. First, it involves targeted 
delivery of the drug to specific tissues or organs. The second function is to deliver the 
drug in a constant and therapeutic rate for a prolonged period of time. Thus, drug 
level in plasma could keep constant within the therapeutic window for a prolonged 
period of time (Curve B of Figure 1.1).  
 
Since Yolls and his co-workers reported the use of the lactide-based copolymers for 
drug delivery in 1970, various polymeric controlled-release systems have been 
                                                                                                                Chapter 1   Introduction                                                                                                                            
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developed. Such drug delivery systems have had an impact on nearly every branch of 
medicine including cardiology, endocrinology, oncology, ophthalmology and 
immunology. In the United States alone, annual sales of advanced drug delivery 
systems have exceeded $10 billion and are still rising rapidly. The world market of 
advanced drug delivery systems is currently valued at $50 billion a year, occupying 
12.5% of world total pharmaceutical sales. By 2005, sales of delivery products are 
predicted to exceed $100 billion (Informa Pharmaceuticals). Investments in the “life 
sciences” industry in Singapore itself are expected to reach S$12 billion dollars by the 
year of 2005. This indicates an increasing support of “life sciences”-related research 














Currently, there are hundreds of protein drugs on the market or undergoing clinical 
trials, which include hormones, growth factors, cytokines, monoclonal antibodies, and 
Figure 1.1 Drug levels in plasma with traditional (Curve A) and advanced 
(Curve B) drug formulations. 
Curve A 
Curve B 
No chemical effect 
Therapeutic window 
Toxic effect 
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proteins for curing various diseases. All the protein drugs share three common 
problems: too large to be delivered through the skin; difficult to be administrated 
orally because of enzymatic degradation; unstable and short half- life in vivo. 
Therefore, protein drugs are required to be given either by constant infusion or 
frequent injections, which limits their acceptability by physicians and patients. 
Polymeric controlled release systems may provide a good approach to improving 
patients’ compliance. Polymeric microspheres as a protein carrier have received 
increasing attention because they can be administrated by injection and protect 
proteins from degradation. My research is aimed at designing such a polymeric 
protein delivery system using a new generation of polymers.  
 
1.2 Goals of the Present Work 
 
In the next chapter, I present an overview of the fundamentals in controlled drug 
delivery including the different types of controlled release systems, drug release 
mechanisms, various polymers used, factors influencing their design and 
performance, the routes of administration, as well as likely future directions.  This 
chapter also presents a review of some of the research work done in this area, in 
particular, the biomaterials being used and the problems associated with protein 
delivery.  An understanding of this will therefore bring into focusing the objectives of 
my project.  Chapter 3 details the methodology of this research project while the 
results obtained are presented and discussed in Chapters 4 and 5. A brief conclusion 
is presented in Chapter 6. 
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All the references cited and papers produced from this research work are listed at the 
end of the thesis as “REFERENCES” and “APPENDICE”, respectively. 














THEORETICAL BACKGROUND AND  
RESEARCH REVIEW 
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In this chapter, I present an overview of the fundamentals in controlled release for 
drug delivery applications. Included here are some basic concepts in controlled 
release, different types of controlled release systems, various polymers used, factors 
influencing release system design and performance, the routes of administration, 
future directions, as well as my research objectives.  
 
2.1 Drug Delivery 
 
Oral administration and injection are conventional ways to administer a drug into 
human body. Compared to injection, oral administration is a more convenient route. 
However, the drug may suffer chemical and enzymatic degradation in the 
gastrointestinal tracts. In addition, the poor availability of drugs is another issue. For 
the injection route, although it is fast in action and has fewer absorption issues, 
patients usually suffer from pain caused by injection. Over the years, scientists have 
been striving to develop various delivery methods in order to increase efficacy of drug 
therapies and improve patient compliance. These methods include insulin pens [1], 
autoinjectors [2], mini-pumps, needleless injectors [3] and controlled drug delivery 
systems [4]. Of these methods, controlled drug delivery has attracted considerable 
attention. Various kinds of polymeric systems have been developed for controlled 
drug delivery. 
 
2.2 Controlled Drug Delivery 
 
In general, controlled drug delivery is classified into the following two categories. 
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· Sustained release: to sustain drug action at a therapeutic rate by maintaining a 
relatively constant, effective drug level in the body for a certain period of 
time. 
 
· Drug targeting : to deliver drug to a specific tissue or organ using carriers or 
chemical conjugates. 
 
In my report, if not mentioned, controlled release means sustained release. The aim of 
a controlled release system is to supply the optimal amount of a drug for a prolonged 
period of time than conventional dosage forms. For example, when the conventional 
tablet is taken repeatedly at fixed internals, its blood kinetics is characterized by the 
"Hill and Valley" phenomenon (Roseman, 1983) (Figure 2.1). The problem associated 
with this phenomenon is that the optimal concentration cannot be maintained and the  
peaks may occur above the toxic level or below the ineffective level. Furthermore, if a 
dosage is delayed or missed, additional difficulties may be incurred. Controlled 
release systems overcome these issues and provide many advantages over the 






















Studies on controlled drug delivery systems were first focused on microencapsulation, 
which began in 1949 with the invention of Wurster process [5]. In 1953, the 
coacervation method was developed and led to the encapsulation of liquid substances. 
Between 1956 and 1966, over 50 patents were filed for microencapsulation 
techniques. Other important drug delivery systems such as implants and transdermal 
patches were reported between the mid-seventies and the early eighties. Since then, 
various advanced drug delivery systems have been developed for different 
applications.  
 
2.3 Advantages of Controlled Drug Release 
 
Controlled drug delivery systems could provide many advantages. A variety of 





Figure 2.1 “Hill and Valley” phenomenon of drug concentration 
when a drug is administered via conventional routes. 
Tablet 1               Tablet 2             Tablet 3 
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ibuprofen, and Nicoderm patches for nicotine addiction, have been commercialized. 
The main advantages that these systems provide include: 
 
· Increased effectiveness 
 
By sustaining the drug concent ration in plasma for a prolonged period of time, 
increased effectiveness of the drug may be obtained. Because the drug is delivered 
more efficiently, smaller doses may be utilized. The side effects to the body could be 
minimized or eliminated.  
 
· Improved patient compliance  
 
Controlled release systems require fewer doses compared to conventional dosage 
forms. Therefore, they are more patient- friendly.  
 
· Lower cost 
 
Applying controlled release systems is more cost-effective because it needs less 
amount of the drug compared to conventional drug formulations.  
 
Besides, to the commercial point of view, pharmaceutical companies are also 
increasingly looking into improving drug delivery as a way to gain a competitive 
advantage. Since developing a new drug is becoming more difficult and expensive, 
more and more pharmaceutical companies are now focusing on the improvement of 
drug delivery systems using the controlled release technology.  
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 2.4 Drug Release Mechanisms Involved in Controlled 
Delivery Systems 
 
An ideal controlled release mechanism for a drug delivery device is the one that 
exhibits zero-order release kinetics, that is, the release of drug is independent of time. 
However, with decreasing of drug level in the device, its release usually slows down. 
Thus, in most controlled release systems, drug release exhibits two phases: an initial 
phase and a second phase that relates to the rapid depletion of the drug from the 
device.  
 
Basically, there are three primary mechanisms involved in the controlled release 
systems by which a drug can be released from a delivery system. They are diffusion, 
swelling followed by diffusion, and degradation.  
 
Diffusion occurs when the drug travels through the polymer matrix into the external 
environment (Figure 2.2). The diffusion can happen on a macroscopic scale—as 
through pores in the polymer matrix, or on a molecular level, by passing between 







Figure 2.2 Release mechanism 1: diffusion. 
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In Figure 2.2, a polymer and a drug have been mixed to form a homogeneous system, 
also referred to as a matrix system. As the drug diffusion continues, its rate normally 
decreases, mainly because the drug has a longer distance to travel and thus requires a 
longer time to diffuse out of the polymer matrix.  
 
For the diffusion-controlled systems, the drug delivery device is fundamentally stable 
in the biological environment and does not change its size either through swelling or 
degradation. In the diffusion-controlled systems, the polymer matrices must allow the 
drug to diffuse through the pores or macromolecular structure of the polymer into the 
biological environment without introducing any change in the polymer itself.  
 
It is also possible for a drug delivery system to be designed so that it is incapable of 
releasing its agent until it is placed in an appropriate biological environment. 
Swelling-controlled systems are initially dry, after being placed in the body, they 
absorb water or other body fluids and then swell. Swelling increases the aqueous  
solvent content within the formulation and the polymer mesh size, enabling the drug 
to diffuse through the swollen network into the external biological environment. One 
example of these types of devices is shown in Figure 2.3. Most of the materials used 
in swelling-controlled systems are based on hydrogels. The hydrogels can absorb a 
great deal of fluid and, at equilibrium, typically comprise 60–90% fluid and only 10–
















One of the most remarkable and useful features of polymer swelling is that swelling 
can be triggered by a change in the environment surrounding the delivery system. 
Dependent on the polymers used, the environmental change can involve pH, 
temperature, or ionic strength. The system can either shrink or swell upon a change in 
any of these environmental factors. For most cases, the structural changes of polymers 
are reversible and repeatable when additional changes in the external environment 
take place.  
 
The controlled release systems described above are based on polymers, the chemical 
structures of which do not change during the course of drug release. However, a lot of 
attentions and research efforts are now concentrating on biodegradable polymers. 
These biodegradable materials can degrade within the body through natural biological 
processes, eliminating the need to be removed after the drug release has been 
completed. Figure 2.4 illustrates an example of degradation-controlled system. 
 
Figure 2.3 Release mechanism 2: swelling. 
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Most biodegradable polymers are designed to degrade into smaller and biologically 
acceptable compounds as a result of hydrolysis of the polymer chains. For example, 
polylactides (PLA), polyglycolides (PGA) and their copolymers (PLGA) hydrolyze 
into lactic acid and glycolic acid, which further break down into carbon dioxide and 
water under physiological conditions. Degradation may take place through bulk 
hydrolysis, in which the polymer degrades in a uniform manner throughout the 
matrix. For some polymers, most remarkably, polyanhydrides and poly (ortho esters) 
(POEs), the degradation may occur only at the surface of the polymer matrices, 
resulting in a release rate that is proportional to the surface area of the drug delivery 






It was reported that the microspheres made from PLGA degraded through bulk 
hydrolysis in water or body fluids, yielding smaller and irregular forms over time [7]. 
In contrast, POE rods showed significant surface erosion after 9 and 16 weeks of 
implantation in rabbits, while the core of the matrices remained intact [8].  
 
2.5 Factors Influencing the Design and Performance of 
Controlled Release Systems 
 
To establish the criteria for design of controlled release products, a number of 
variables must be taken into considerations. 
Figure 2.4 Release mechanism 3: degradation. 
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· Drug properties: the physicochemical properties of a drug, including stability, 
solubility, charge, and protein binding propensity etc., play an important role in 
the design and performance of controlled release systems. 
 
· Target sites: in order to minimize side effects, it is desirable to maximize the 
fraction of applied dose reaching the target organ or tissue. This can be partially 
achieved by local administration or by the use of carriers. However, the absorptive 
surface of most routes is impermeable to macromolecules or other targeted 
delivery systems, thereby necessitating either intra-vascular or intra-arterial 
administration. 
 
· Route of drug delivery: the area of the body in which drugs will be applied or 
administered can be restrictive on the basis of technological achievement of a 
suitable controlled release mechanism or device. At times, the drug delivery 
system, in certain routes of administration, can exert a negative influence on drug 
efficacy, particularly during chronic administration, and hence other routes of 
administration should be considered. Performance of the controlled release 
systems may also be influenced by physiological constraints imposed by the 
particular route, such as first-pass metabolism, GI motility, blood supply, and 
sequestration of small foreign particles by the liver and spleen. 
 
· Acute or chronic therapy: consideration of whether one expects to achieve cure 
or control of a condition and the expected length of drug therapy are important 
factors in designing controlled release systems. Attempts to generate a one-year 
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contraceptive implant present significantly different problems in design from 
dosing an antibiotic for acute infection. Moreover, long-term toxicity of rate-
controlled drug delivery systems is usually different from that of conventional 
dosage forms [9]. 
 
· The disease: pathological changes during the course of a disease can play a 
significant role in the design of a suitable drug delivery system. For example, in 
attempting to design an ocular controlled-release product for an external 
inflammation, the time course of changes in protein content in ocular fluids and in 
the integrity of the ocular barriers would have to be taken into consideration. 
Sometimes, one can take advantage of the unique manifestations of the disease 
state. For example, the higher plasminogen activator levels in some tumor cells 
can lead to preferential bioconversion of peptidyl prodrugs in these cells [10]. 
Similarly, the higher tyrosinase level in melanoma cells has been demonstrated to 
allow the preferential bioconversion of 2,4-dihydroxphenylalanine in them [11]. 
 
· The patient: whether the patient is ambulatory or bedridden, young or old, obese 
or gaunt, etc., can influence the design of a controlled release product. An implant 
or intra-muscular injection of a drug to a patient with little muscle movement may 
perform in a manner significantly different from that of an ambulatory patient. 
Some of these factors represent individual patient variation and cannot be 
controlled by the research scientists. For example, single unit controlled release 
products are particularly prone to intra- and inter- subject variation because of 
variability in individual GI motility [12]. 
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From the previous discussion, it is clear that the formulation and performance of 
controlled release dosage forms depend on the physicochemical properties of the drug 
and its carrier. The pharmacokinetics and pharmacodynamics, to a large extent, are 
derived from the intrinsic properties of the drug. Thus, development and assessment 
of a controlled drug delivery system require a rather complete knowledge of the 
intrinsic properties of a drug and the ways in which it can influence the design of 
controlled release systems. In some cases, undesirable physicochemical and biological 
properties can be altered by suitable chemical modification, by use of a carrier, or 
perhaps by administration via another route.  
 
2.6 Routes of Controlled Drug Delivery 
 
Because of the significant advantages that controlled release systems provide, the list 
of controlled release products continues to grow, particularly in cost-neutral or cost-
advantageous situations. There are some cases where controlled delivery is actually an 
enabling technology for a drug. For example, the drug is unstable or highly toxic 
without the controlled delivery devices. The most active areas for development, 
marketing, production, and sales of controlled delivery products are human 
pharmaceuticals, veterinary pharmaceuticals, cosmetics, and agricultural products. 
  
Controlled release systems have already been found in a wide variety of applications 
in human medication, which have been delivered through various routes. Below is a 
brief description of some of these routes. 
 
 












· Oral delivery 
 
Oral administration is the most widely used route because of its simplicity and 
convenience. Problems, however, include the hostile environment of the 
gastrointestinal route as well as poor solubility of the polymeric materials in the 
various cellular barriers [13-14]. Adding to these constraints is the commonly 
substantial intra- and inter-subject variability associated with some of these factors. 
Generally, these factors cannot be controlled and hence severely limit the design of 
oral drug delivery systems. 
 
Various approaches include using polymers that degrade preferentially in the colon, 
nanoparticles that can be taken up by intestinal Peyer’s patches, and bioadhensives 
that interact strongly with intestinal mucosa. Hydrogels and osmotic pumps are two of 
the important classes of oral controlled-release dosage forms. 
 
Figure 2.5 Some routes of drug delivery. 
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· Transdermal delivery 
 
In the past, topically applied determatological drugs were used for localized treatment 
of skin diseases only. Recently, due to a better understanding of the anatomy and 
physiology of the skin as well as a more thorough understanding of percutaneous 
absorption, the limited permeability of human skin has also been utilized for systemic 
drug administration.  
 
Transdermal patches, together with oral forms, are the most extensively developed 
because both transdermal and oral delivery are non- invasive. Almost all prescription 
medicines fall into these two categories. An advantage that transdermal delivery 
provides is that the drug enters the systemic circulation directly, avoiding liver 
metabolism and gastrointestinal incompatibility. Drugs such as scopolamine [15], 




· Parenteral delivery 
 
Strictly speaking, parenteral products include all systems administered outside of the 
GI tract. However, parenteral routes are more commonly restricted to injectable 
administration such as subcutaneous, intramuscular, intraperitoneal, intrathecal, and 
Figure 2.6 A 3Mâ transdermal patch. 
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intraventricular injection. Generally, for life-threatening diseases or those in which the 
quality of life is drastically impaired, injectable controlled-release administration may 
be appropriate. 
  
Currently, proteins are mostly administered via the parenteral route. Since proteins 
have short half- lives, efforts have been made to design controlled release parenteral 
delivery systems. Products based on PLGA and a small peptide, luteinising hormone 
and releasing hormone (LHRH) are on the market. More recently, microspheres 
containing recombinant human growth hormone have been developed and marketed 
successfully [18]. 
 
· Pulmonary delivery 
 
Delivery of a drug to the respiratory tract for localized therapy of respiratory diseases 
is commonly accomplished via the airways because of their enormous surface area 
and accessibility [19]. Research has shown that many molecules are absorbed through 
the deep lung into the bloodstream without the need for enhancers used by other non-
invasive routes. This high bioavailability makes the lung a natural target for peptides, 
proteins and small molecules. The structure of the lung is shown in Figure 2.7* . 
 
Success of pulmonary delivery will depend on a number of factors. First, the drug 
used in aerosols must be quite potent but with negligible systemic side effects. 
Second, the drug must be able to gain access to its target site. Third, the drug must 
bind to tissue components thereby providing a high local concentration for prolonged 
                                                 
*  From Chemtech 27 (2), pp34-38, 1997. 
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periods. Finally, good aerosol delivery from nebulizers is needed to enhance the 
amount of drug reaching the lung. Nevertheless, controlled delivery of drugs to the 
respiratory area is useful mainly for localized treatment of inflammation or cancer. It 





· Buccal/sublingual delivery 
 
Buccal drug delivery seems to combine the advantages of transdermal and oral 
delivery. Drug can be absorbed from the oral cavity through the oral mucosa either 
sublingually (under the tongue) or buccally (between the cheek and gingival). In 
general, rapid absorption from these routes is observed because of the thin mucous 
membrane and rich blood supply. For highly hydrophilic drugs, which also suffer 
from extensive pre-systemic elimination and require a rapid onset of action, 
sublingual or buccal administration may offer advantages over oral administration. 
After absorption, drug is transported through the deep lingual vein or facial vein. 
Thus, the buccal and sublingual routes can be used to bypass hepatic “first-pass” 
elimination. 
 
Figure 2.7 Pulmonary delivery via alveolar site. 
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Conventional buccal and sublingual dosage forms are typ ically short acting because 
of limited contact time between the dosage form and the oral mucosa. Since 
sublingual administration of drugs interferes with eating, drinking, and talking, this 
route is generally considered unsuitable for prolonged administration. Compounds 
administered by either the buccal or sublingual route include steroids, barbiturates, 
papain, trypsin, and streptokinase-streptodornase [20]. 
  
2.7 Controlled Delivery Devices 
 
In recent years, there have been numerous developments in polymeric carriers for 
controlled drug delivery. A few examples reported in the literature include:  
 
· Films with a drug in a polymer matrix (monolithic devices) [21-23];  
· The drug contained by the polymer (reservoir devices) [24];  
· Polymeric colloidal particles or microencapsulates (microparticles, 
microspheres or nanoparticles) in the form of reservoir and matrix 
devices [22, 23];  
· The drug contained by a polymer containing a hydrophilic and/or 
leachable additive such as a second polymer, surfactant or plasticizer 
to give a porous device, or a device in which the drug release may be 
osmotically controlled (both reservoir and matrix devices) [25-28];  
· Enteric coatings that are ionized and dissolved at a suitable pH [26];  
· Soluble polymers with covalently attached pendant drug molecules 
[29-33]; 
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· Devices such as osmotic pumps where drug release rate is controlled 
dynamically [34].  
 
2.7.1 Reservoir devices 
 
A typical approach to controlled release is to encapsulate or contain a drug entirely 
within a polymer film or coat (e.g. microcapsules or spray/pan coated cores). Film 
coatings have been reviewed by Kala et al. [35], and microencapsulation has been 
summarized by Arshady et al [36, 37].  
 
Various factors such as additives, polymer functionality, porosity and film casting 
conditions that can affect the diffusion process should be taken into considerations for 
the design of desired reservoir devices.  
 
When the device contains a water-soluble drug, the release rate of the drug decreases 
with time as the drug concentration, the driving force for the drug release, within the 
device decreases. However, if the drug is in a saturated suspension, the driving force 
is kept constant until the device is no longer saturated. Thus, zero order release is 
achieved [38, 39]. Alternatively, the drug release may undergo a desorption-
controlled mechanism and it is then a function of the square root of time.  
 
Transport properties of coated tablets can be enhanced compared to tablets without a 
polymer film since the coating layer may help build up an osmotic pressure that may 
accelerate drug release [28].  
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2.7.2 Monolithic devices 
 
Monolithic devices are possibly the most common drug delivery systems. This is 
because they are easy to fabricate compared to reservoir devices. In addition, there is 
no danger of an accidentally high dosage that could result from the crack of the 
membrane of a reservoir device. In such a device, a drug is dispersed within a 
polymer matrix. Monolithic devices are normally formed by the compression of a 
polymer/drug blend or by dissolution or melting.  
 
2.7.3 Other Types of Controlled Release Devices 
2.7.3.1 Pendent devices  
 
Scholsky and Fitch (1986) [40] developed a means of attaching a variety of drugs 
such as analgesics and antidepressants through an ester linkage to poly (acrylate) ester 
latex particles prepared by aqueous emulsion polymerization. These latices could self-
catalyze the drug release by hydrolysis of the ester linkage when they passed through 
an ion exchange resin so that the polymer end groups were converted to their strong 
acid form. [29, 31] 
 
2.7.3.2 Enteric films 
 
Enteric coatings consist of pH-sensitive polymers. Typically the polymers are 
carboxylated and can hardly dissolve in water at low pH, while at high pH the 
polymers are ionized, resulting in swelling, or dissolving of the coatings. Coatings can 
therefore be designed to remain intact in the acidic environment of the stomach but to 
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dissolve and release their contents rapidly when they reach the more alkaline 
conditions of the upper intestines. For example, EUDRAGITÒL 100, a product of 
Röhm Pharma Polymers, is a pH dependent anionic polymer powder solubilizing at 
above pH 6.0 for targeted drug delivery in the ileum. 
 
2.7.3.3 Osmotic pumps 
 
Osmotic pumps contain an osmotic agent (e.g., a drug in a salt form), which absorbs 
water from the surrounding medium via a semi-permeable membrane. Such a device 
called the elementary osmotic pump, was described by Theeuwes et al (1975) [34]. 
Figure 2.5 illuminates an example of osmotic pumps. The active agent serves as the 
osmotic agent, which is surrounded by the rigid semi-permeable membrane 
containing a delivery orifice. When the pump is immersed into an aqueous medium, 
pressure is generated within the device and drives the drug out of the device through 
an orifice. Since the internal volume of the device remains constant and there is an 





















2.7.3.4 Electrically stimulated release devices 
 
Yuk et al. [41] prepared monolithic devices using polyelectrolyte gels that swelled when 
an external electrical stimulus was applied. The drug release could be modulated by 




Hydrogels are not only used as a drug carrier but also find a number of applications in 
bioengineering (e.g. soft contact lenses and various soft implants) [42, 43]. Recently, 
stimuli-sensitive hydrogels have attracted considerable attention, which could respond to 
small external stimulus changes, such as temperature [44] (Figure 2.9), pH [45], photo 
field [46] and antigen [47]. This unique responsive property makes this hydrogel 
especially useful for biomedical and bioengineering applications such as 





containing a drug Semi-permeable membrane 
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protein- ligand recognition [48], on-off switches for modulated drug delivery [49-51] 






In the following paragraphs, polymeric microspheres systems for controlled drug 
delivery will be introduced. Section 2.9 will provide an overall view of the polymers 
used in controlled drug delivery systems. 
 
2.8 Drug Delivery Based on Polymeric Microspheres 
2.8.1 Background - Microencapsulation 
 
Microencapsulation is one of the most intriguing fields in the area of drug delivery. It 
requires knowledge of polymer science, familiarity with emulsion technology and an 
in-depth understanding of drug and protein stabilization. Some journals are now 
solely dedicated to the area of microencapsulation (e.g. Journal of 
Microencapsulation). Although scientists at the beginning of the 1970s were 
primarily concerned with the encapsulation of dyes to produce carbonless paper, 
Figure 2.9 Changing of viscosity of hydrogel with increased temperature. 
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today the technology has been mastered to such a level that cells as well as delicate 




Microspheres are produced by a kind of microencapsulation technique. Theoretically, 
microspheres are spherical particles with a size range from 1 to 1000 µm. An active 
ingredient may be dispersed in a hydrophilic or non-biodegradable matrix, or may be 
enveloped by a release-modulating polymer layer. Figure 2.10 shows a cross-section 






The microsphere system is suitable for oral, pulmonary and injection administration. 
It is a good approach to delivering proteins through parenteral routes [54, 55]. Among 
the various biodegradable polymers such as PLA, PGA, PLGA, polyanhydrides, and 
POEs, PLGA has been widely utilized for microspheres fabrication for controlled 
delivery of peptides, native and synthetic proteins and lately, nucleic acids. The 
PLGA microspheres have a size ranging from 1 to 250 µm. Many factors are 
important to formulate this system: 1) polymer molecular weight, monomer ratio and 
morphology, which determine drug release rate; 2) particle size, which is important in 
terms of interaction with phagocytic cells; 3) safety, which is related to the in vivo 
polymer degradation, and 4) stability, both in storage and in the biological fluids.  
Figure 2.10 Cross-section of a microsphere. 
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2.8.3 Microspheres preparation --- a double emulsion process 
 
There are several ways to prepare microspheres, including single/double emulsion, 
spray drying and other processes. Among these methods, the water-in-oil- in-water 
(W/O/W) double emulsion technique is the most commonly used one. The choice of a 
method depends on the physical and chemical properties of the drug as well as the 
polymers. 
 
A typical W/O/W double emulsion process for microspheres fabrication is shown in 
Figure 2.11 [84]. The inner aqueous phase containing a hydrophilic drug is emulsified 
with an immiscible polymer solution by sonication to produce a primary emulsion. 
This first emulsion is homogenized with an aqueous solution containing a surfactant 
to yield a W/O/W double emulsion. Water is added to the double emulsion with 
stirring to extract the solvent from the oil droplets to the external water phase. After 
that, the microspheres are filtered, washed with water and then dried. The 
composition of the aqueous phase, polymer concentration as well as the surfactant 
applied play an important role in the pattern of drug release since porosity and water 
permeability of the resultant microspheres depend on these factors. The W/O/W 
double emulsion method is suitable for the encapsulation of hydrophilic drugs. 
However, it has also been employed to produce lipophilic molecules-containing 
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2.9 Polymers Used in Controlled Drug Delivery Systems 
 
In a polymeric drug delivery system, the polymer is used as a protectant of a drug 
during the drug's transfer through the body until it is released, or used to control the 
release rate of a drug. Selecting a suitable polymer is critical to the design of a desired 
controlled release system. 
 
2.9.1 Polymer characteristics 
 
There are three characteristics that describe an ideal polymer used for drug delivery. 
First, the polymer must be biocompatible and degradable. This means that the 
polymer should degrade in vivo to smaller fragments that can then be excreted from 
the body. If a polymer matrix fails to degrade inside the body, then it must be 
surgically removed after the drug is released. Second, the degradation products of the 
polymer must be nontoxic and not triggering any inflammatory response. Third, the 
degradation of the polymer should occur within a reasonable period of time.  
 
2.9.2 Biologically degradable polymers 
 
Biologically degradable polymers are defined as a class of polymers that can degrade 
into smaller segments due to the presence of chemicals inside the body. 
Biodegradable polymers and bioabsorbable polymers are the two kinds of degradable 
polymers that have the ability to break down in this manner. Biodegradation can be 
described as degradation that is promoted by enzymes. In other words, enzymes that 
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are present within the body break down polymers. Bioabsorbable polymers are those 
that are degraded by other chemicals in the body. Both biodegradable and 
bioabsorbable polymers have been used for controlled drug delivery.  
 
Biologically degradable polymers include natural, modified natural and synthetic 
polymers. Collagen, cellulose, and chitosan are examples of natural polymers. Natural 
polymers have been tested as drug delivery matrices for the delivery of protein based 
drugs. Modified natural polymers are natural polymers that are altered in order to suit 
a particular application. The reason for modification is that these polymers often take 
longer time to degrade within the body. By adding polar functionalities to the 
polymers, the problem could be overcome since the polar groups are more flexible 
and can therefore promote the degradation of the polymers.  
 
The addition of functional groups may change the physical and chemical properties of 
the polymers. In the process of modifications of natural polymers, the nature and 
extent of modification should be considered. If a polymer is modified in excess, the 
natural polymer may not degrade easily. In addition, the added functional groups may 
be converted to toxic degradation products.  
 
Over the past few decades, synthetic polymers have been actively studied for use in 
drug delivery systems. Polyesters, polyurethanes, polyanhydrides and poly (ortho 
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2.9.3 Classification of synthetic biodegradable polymers 
 
In broad terms, synthetic  polymers may be classified as either biodegradable or non-
biodegradable. Biodegradable polymers have recently captured much attention mainly 
because non-biodegradable systems need retrieval or further manipulation after 
introduction into the body. 
 
In the realm of biodegradable polymers, there exists another level of classification 
based upon the mechanism of polymer erosion. Two erosion mechanisms can be 
identified, including surface and bulk erosion. In practical terms, these two 
mechanisms represent extremes. For most biodegradable polymers, both mechanisms 
will occur. However, the relative extent of surface or bulk erosion varies depending 
on the chemical structure of the polymer backbone.  
 
Surface erosion occurs when the rate of polymer erosion is equal to or exceeds the 
rate of water permeation into the bulk of the polymer. This is often considered to be a 
desirable mechanism in drug delivery because the kinetics of erosion, and hence the 
rate of drug release, is highly reproducible. In an ideal surface erosion process, the 
erosion rate is directly proportional to external surface area. Surface erosion can lead 
to zero-order drug release as long as diffusional release is limited and the overall 
shape remains constant. 
 
Bulk erosion occurs when water molecules are able to permeate into the bulk of the 
polymer matrix at a faster rate than erosion. As a consequence, polymer molecules in 
the bulk may be hydrolyzed and the kinetics of polymer degradation/erosion is more 
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complex than surface eroding polymers. The majority of biodegradable polymers used 
in controlled drug delivery undergo bulk erosion, including the very important 
materials, poly (esters).  
 
Hopfenberg [57] derived expressions for drug release from erodible slabs, cylinders 
and spheres. If the erosion rate is proportional to the continuously changing surface 









where Mt = mass released at a given time t 
M¥ = initial incorporated mass 
k0 = erosion constant 
  t = time 
  C0 = initial uniform concentration of drug in matrix  
  a = radius of sphere/cylinder or half -thickness of a slab 
  n = 3 (sphere), 2 (cylinder), 1 (slab)  
 






















Figure 2.12 Classification of polymers used in controlled drug delivery. 
 
2.9.3.1 Poly (esters) 
 
Poly (esters) are the most widely studied biodegradable materials, including PLA, 
PGA, and PLGA (Figure 2.13). 
 
The degradation mechanism of poly (esters) is classified as bulk degradation with 





 Figure 2.13 Chemical structure of PLGA. 
Polymers in Controlled Drug Delivery 
broadly classified as either 
Non-Biodegradable Biodegradable or 
e.g. poly (ethylene), poly (acrylamide), 
poly (N-isopropyl acrylamide) 
 
which can be further divided into 
Surface eroding Bulk eroding 
e.g. poly (lactic-co-glycolic acid), poly 
(phosphoester), poly(ortho esters) 
 
e.g. p o l y  ( o r t h o  e s t e r ),  
poly (anhydrides),  
 
e.g. poly (lactic-co- 
glycolic acid) 
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2.9.3.2 Poly (ethylene glycol) block copolymers 
 
Poly (ethylene glycol) (PEG) is an outstanding biocompatible material. One of the 
emerging uses for inclusion of PEG in a controlled release system arises from its 
interaction with protein. Conjugation of proteins with PEG has proved to be able to 
provide prolonged protein circulation life, reduced immunogenicity and antigenicity 
[58]. PEG chains at the surface provide the incorporated substance longer circulation 
time in the body by prolonging biological events such as endocytosis, phagocytosis, 
liver uptake and clearance, and other adsorptive processes. [59-63]  
 
PEG can be made with a range of terminal functionalities, which lead to its easy 
incorporation into copolymer systems. PEG is commonly terminated with chain-end 
hydroxyl groups that provide a ready handle for synthetic modification. Diblock PLA-
PEG and triblock PLA-PEG-PLA systems have been synthesized and characterized 
with various PLA contents [64-68]. Jeong et al. prepared thermo-sensitive PLA-PEO 
hydrogels that exhibit temperature-dependent gel-sol transition for use as injectable 
drug delivery systems. [69] 
 
2.9.3.3 Poly (ortho esters) 
 
The motivation for designing poly (ortho esters) for drug delivery was the need to 
develop biodegradable polymers in which drug release exhibits surface erosion 
mechanism. [70]  
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Most studies on poly (ortho esters) have focused on the synthesis of polymers by the 
addition of polyols to diketene acetals. For example, Heller et al. [71] have described 
the synthesis and application of the 3,9-diethylidene-2,4,8,10-tetraoxaspiro[5,5] 
undecane (DETOSU)-based poly (ortho esters). The basic structure is formed by the 
addition of the DETOSU monomer to a diol to form the chemical structure shown in 
















The DETOSU-based poly (ortho esters) contain acid labile ortho ester linkages in 
their backbone. In aqueous environments, the ortho ester groups are hydrolysed to 
form pentaerythritol dipropionate and  diol monomers (Figure 2.14). The 
pentaerythritol diopropionate is further hydrolyzed to pentaerythritol and acetic acid. 
Figure 2.14 Degradation of the 3,9-bis (ethylidene-2,4,8,10-
tetraoxaspiro[5,5]undecane) (DETOSU)-based poly(ortho esters). 
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The acid-catalyzed hydrolysis of POE can be modulated by introducing either an 
acidic or a basic excipient into the matrix system. The rate of hydrolysis is increased 
by the addition of acidic excipients [72]. Alternatively, basic excipients stabilize the 
bulk of the matrix but diffuse out of the surface region, thereby facilitating surface 
erosion [73]. This approach has been employed in the temporal controlled release of 
tetracycline over a period of weeks in the treatment of periodontal disease [74]. 
 
Recently, a number of changes in diol structure have been attempted to avoid the need 
for acidic excipients. These new poly (ortho ester) structures address the problem of 
acidic excipient diffusion from matrices, which leads to unpredictable degradation 
kinetics. Ng et al. described the synthesis of self-catalyzed poly (ortho esters) that 
contain glycolide segments [75]. Once glycolide segments degrade, its degradation 
products catalyze ortho ester bond breakage, hence forming a self-catalyzing system. 
The synthesis of these polymers is shown in Figure 2.15. 
 
A useful feature of the DETOSU systems is the ability to control the mechanical 
properties by changing the diol monomer ratios within the final polymeric structure. 
For example, Heller et al. have shown that the glass transition temperature of 
polymers containing a rigid diol monomer (trans-cyclohexanedimethanol) (CDM) and 
a flexible monomer (1,6-hexanediol) could be varied between 20 and 105°C by 
increasing the proportion of the rigid diol [70]. This control can also be achieved with 
the glycolide-containing polymers [75]. 
 
 
















2.9.3.4 Polymer Properties Influencing Drug Release 
 
Drug release from a polymeric matrix is affected by various factors including drug 
nature, polymer properties and morphology of the matrix. Two important polymer 
properties that influence drug release are described below. 
 
a) Molecular weight and molecular weight distribution. Molecular weight 
reflects the size and size distribution of a polymer. While we may expect 
qualitatively that drug diffusion rate decreases with increasing molecular 
weight, the critical factor that governs drug diffusion is determined by the 
Figure 2.15 Synthesis of a self-catalyzed poly (ortho ester) containing glycolic 
acid dimer. 
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overall microstructure of the polymer in the presence of diffusing and 
other foreign species. 
 
b) Transition temperature. The glass transition temperature can be modified 
by changing the strength of the secondary forces within the polymer. This 
can be accomplished by introducing an additive, such as a plastizer, to the 
polymer. Another approach to modifying the glass transition temperature 
is to form a copolymer. Drug transportation is modeled by a migration of 
the penetrant through holes or free volume within the polymer. Therefore, 
the rate of transport is based on the probability of creating a hole of 
sufficient size to accommodate the penetrant, and the probability for this 
penetrant to have sufficient energy to enter this hole. At temperatures 
significantly higher than the Tg, both probabilities must be taken into 
account to estimate diffusivity. However, near the Tg, the amount of free 
volume is small, so the probability of encountering holes of sufficient size 
dominates mass transfer. In most cases, when the temperature is lower 
than the glass transition temperature, the amount of free volume is small, 
and the redistribution of holes within the polymer is negligible because 
segmental motion is virtually nonexistent. 
 
2.9.3.5 Factors to Be Considered in Selecting A Polymer for 
Controlled Drug Delivery 
 
There are several important factors to be considered in selecting or developing a 
polymer for controlled drug delivery: 
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· Biocompatibility and toxicity 
· Regulatory acceptance or concerns 
· Degradation rate, degradation products, and biocompatibility as well as 
toxicity of the degradation products 
· Cost 
· Chemical, physical, and mechanical properties 
· Processing requirements 
· Compatibility of the drug with the polymer 
· Required sterilization methods 
· Glass transition temperatures 
 
The relative importance of these factors varies depending on the particular 
application. For example, if the product contains a thermally sensitive active agent, a 
polymer requiring thermal processing might not be acceptable. 
 
2.10 Protein Delivery and a Model Protein - Bovine Serum 
Albumin (BSA) 
 
Efficacious delivery of proteins and peptides is taking on increasing significance as 
biotechnology companies mature and begin commercializing their products. As a 
result, there has been increasing interest in the development of protein and peptide 
delivery systems. The high level of interest is attributed to several factors. As the 
pharmaceutical and biotechnology industries consolidate and mature, there is an 
interest in value-added technologies, which drug delivery systems can provide. There 
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is also an impending stream of patent expirations, which is fueling the demand for the 
rapid development of new products that may be realized by drug delivery 
technologies. 
 
Proteins are polymers made up mainly by amino acids, which polymerize to give long 
chains that then fold into a functional 3-dimensional structure. Proteins must maintain 
this structural and chemical integrity to function properly. This 3-dimensional 
structure, however, is held in place by weak forces that can be easily broken. Once 
this configuration is destroyed, the proteins lose their activity, and are essentially 
denatured. Proteins can lose their activity easily when subjected to adverse conditions 
such as high temperature, mechanical agitation and extreme pH etc. 
 
For a long period of time, controlled release devices were only capable of slowly 
releasing drugs of only low molecular weight (<600). Large molecules such as 
proteins were considered too large to slowly diffuse through most of the polymeric 
materials. It could diffuse through highly porous membranes, e.g. Millipore filters or 
certain gels such as polyacrylamide. However, the diffusion was too rapid and could 
result in tissue damage. The discovery that matrices of solid hydrophobic polymers 
enable molecules of any size to be released for over 100 days allows the controlled 
delivery of a variety of proteins. Non-degradable ethylene-vinyl acetate and 
degradable lactic-glycolic acid copolymers are materials that are capable of 
performing the task. Certain hydrogels such as poly (hydroxyethylmethacrylate) or 
poly (vinyl alcohol) are also effective but they release proteins in a shorter period of 
time. 
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There are still problems facing protein delivery. The most significant issue is the 
denaturation, degradation and aggregation of the encapsulated proteins when they 
remain in the body for long time. It can cause a loss of biological activity as well as 
changes to its immunogenicity. To circumvent these problems, several approaches 
have been explored in order to protect proteins from aggregation and degradation 
using stabilizing excipients [76-78]. Protein stabilization is one of the most important 
issues, which the researchers must take into considerations during the design of 
controlled release systems. 
 
BSA is a commonly used model protein during the development of controlled release 
systems [79]. It is known for its surface-active property, which is responsible for its 
deposition at the oil-water interface [80]. This has a strong stabilizing effect on the 
first emulsion [81] in the double emulsion (W/O/W) process and leads to the 
formation of a matrix- like structure. 
 
BSA in a solid form is stable for about three years when stored at +2 to 8°C. In our 
research, BSA, with a molecular weight of 58 kDa, is used as the model protein to 
explore polymeric microsphere systems suitable for protein delivery.  
 
2.11 Future Directions of Controlled Drug Delivery 
 
Advances in nanotechnology are expected to contribute significantly to further 
development of drug delivery systems. In the near future, we anticipate the drug 
delivery industry will continue to be an important segment of the pharmaceutical 
industry. We expect to see more and more pharmaceutical companies competing to 
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explore drug delivery technologies and improved drugs. These reformulation 
opportunities only exist because drug delivery technologies were not harnessed before 
the branded products’ patent expirations. 
 
In conclusion, the market of controlled drug delivery has become a long way and will 
continue to grow at a significant rate. Since more and more large pharmaceutical 
companies are involving in the development of new controlled drug delivery 
technologies, tomorrow’s drug will definitely be more challenging because of the 
development of drug delivery systems.  
  
2.12 Research Objectives 
 
Currently, POE polymers are receiving significant attention because some of them 
undergo surface-dominant erosion and consequently control erosion rates. POE 
polymers have been used to encapsulate water-soluble drugs such as 5-fluorouracil 
and proteins within microparticles using a double emulsion solvent 
evaporation/extraction technique [82, 83]. It has been proved that POE polymers 
provided a friendly environment for proteins. However, since POE is a highly 
hydrophobic polymer, the affinity between POE and the water-soluble protein is 
weak. This yields an unstable emulsion and leads to a poor protein encapsulation 
efficiency. When PEG is built into the POE chain such as POE-PEG-POE block 
copolymers, or blended with POE, it can be expected that the triblock copolymer and 
the POE/PEG blend will stabilise the protein and enhance protein encapsulation 
efficiency. Based on these promising polymer systems, our research focuses are 
summarized as follows:   
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1. To fabricate POE/PEG blend and POE-PEG-POE triblock copolymeric 
microspheres, and to investigate the morphology, particle size, protein 
distribution and protein encapsulation efficiency of the microspheres under 
different fabrication conditions. 
 
2. To study the degradation and erosion mechanism of the microspheres. In 
addition, to explore the stability of an encapsulated protein and its release 
properties.  
 
3. To improve protein release profiles based on the understandings of protein 
release and polymer erosion mechanisms.  













   
MATERIALS AND METHODS 
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The materials and methodology used in the course of the research project are 
presented below.  Included are the methods for microsphere preparation as well as 





PEG polymers, with number molecular weight of 4,600, 100,000 and 200,000, were 
purchased from Sigma-Aldrich Company. POE and POE-PEG-POE triblock 
copolymers having a 4,600 or 1,000 number molecular weight of poly (ethylene 
glycol) (PEG) were synthesized and supplied by AP Pharma. Inc., USA. The 
synthesis of POE-PEG-POE was described in Section 3.2. The PEG content ranges 
from 5% to 30%. Table 3.1 lists the properties of POE-PEG-POE triblock 






















(A/B/C: CDM/TEG/TEG-diGL; x:y:z=94:5:1; when A and B stand for 1,2-PrD/1,2-PrD-diGL, x:y=95:5,  















Copolymer type PEG Content (in 
weight) 
Mw 
POE 0 46.0k 
POE-PEG(5%)-POE 5% 41.6k 
POE-PEG(10%)-POE 10% 36.9k 
POE-PEG(20%)-POE 20% 23.3k 




Bovine serum albumin (BSA) (fraction V, 58kDa), used as the model protein, was 


















C H 2 O C
O
C H 2 O H
Table 3.1 Properties of POE-PEG-POE triblock copolymers. 
TEG-diGL 
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3.1.3 Emulsifiers and solvents 
 
Poly (vinyl alcohol) (PVA) (87-89 mol % hydrolyzed, Mw 31,000-50,000) and 
polyoxyethylene-sorbitan monooleate (Tween 80) were purchased from Sigma-
Aldrich Company. Methylene chloride (L. C. grade) was purchased from Merck. 
Deuterated chloroform (CDCl3) was purchased from Sigma Company.  All other 
chemicals were of reagent grade and used as received. 
 
3.2 Synthesis of POE-PEG-POE Triblock Copolymers 
 
The synthesis of the POE-PEG-POE triblock copolymers was carried out in AP 
Pharma. Inc., USA, which is illustrated by the following example of POE-PEG-POE 
with a PEG content of 5% in weight and a number molecular weight of 4,600. 
 
Under an anhydrous condition, the mixture of 3,9-diethylidene-2,4,8,10-
tetraoxaspiro{5,5} undecane (DETUSO) (21.225g, 100 mmoles) and PEG (Average 
Mn = 4,600, 2g, 2 mmoles) was dissolved in 40 ml of tetrahydrofuran (THF).  After 
addition of p-toluenesulfonic acid (PTSA)/THF solution (0.05 ml, 20 mg/ml), the 
reaction mixture was stirred for 30 minutes. Next, the solution of trans-
cyclohexanedimethanol (CDM) (13.29g, 92.12 mmoles), tri (ethylene glycol) (TEG) 
(0.736g, 4.9 mmoles) and tri(ethylene glycol)-diglycolide (TEG-diGL) (0.216g, 0.98 
mmoles) in THF (40ml) was added to the reaction mixture. After another portion of 
PTSA/THF solution (0.05ml, 20 mg/ml) was added, the reaction mixture became 
boiling. The solution was stirred until it cooled to room temperature. The polymer 
was precipitated from 1.5L of methanol containing 0.5 ml of triethylamine as a 
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stabilizer, and dried in a vacuum oven, first at 30°C overnight then at 80°C for 5 
hours. 
 
3.3 Polymeric Microspheres Preparation 
 
BSA-loaded POE, POE-PEG-POE and POE/PEG blend microspheres were prepared 
using an improved double-emulsion (water-in-oil- in-water) solvent 
evaporation/extraction procedure [84]. Briefly, 600mg polymer (or polymer blend) 
was dissolved in 12ml methylene chloride. After that, 0.3 ml*  of BSA-containing PBS 
solution (the internal aqueous phase) was emulsified in the polymer solution for 15 
seconds by sonication to produce a primary W/O emulsion. This emulsion was 
injected with stirring into 250 ml of PBS solution containing PVA as an emulsifier 
(the external aqueous phase) to produce a W/O/W double emulsion. The solution was 
maintained at 15ºC with stirring for 30 minutes using a mixer (Cole-Parmer 
Instrument Co., IL USA). Then, 640 ml of PBS containing PVA was added at a rate 
of 3 ml/min for about four hours. The resultant microspheres were filtered, washed 
and vacuum-dried overnight and stored at 4°C before use.  
 
3.4 Evaluation of Protein Encapsulation Efficiency 
 
The BSA amount lost in the external aqueous phase during the fabrication process 
was analyzed using a high performance size exclusion chromatography (HPSEC). 
The HPSEC system consisted of a 1050 Quatern Pump, a 1100 autosampler injector 
and a Diode-Array UV detector. A Zorbax GF-250 column (4.6 mm ´ 25 cm, Dupont 
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Company) was used as the separation column. The flow rate of the mobile phase 
(PBS, pH 7.0) was 1.0 ml/min and the UV detection was at 210 nm. The 
encapsulation efficiency was calculated as the ratio of actual and theoretical BSA 
content as illustrated in equation 3.1: 
                                                                                   
                                                                              BSA encapsulated, mg 
BSA Encapsulation Efficiency (EE) %=                                                               ´100% 
          Theoretical amount of BSA fed, mg 
 
 
3.5 Determination of Inherent Viscosity (hinh) of Polymer 
Solution 
 
The inherent viscosity of POE, POE-PEG-POE copolymer and POE/PEG polymer 
blend in methylene chloride was determined according to ISO/DIS 3105 and ASTM 
D2515/D446 using the Schott Gerate AVS360, Viscometer: DIN Ubbelohde (Type: 
Capillary No. 52510/I Appt. No. 904473) at 25 °C. The inherent viscosity is 





)/ln( 0=h  
                                    where t0 is flow time of solvent, 
                                              t is flow time of polymer solution and 
                                             C is the concentration of the sample in g/dL. 
                                                                                                                                                                                          
*  * If there is no further mentioning, the internal aqueous phase is  always 0.3ml. 
(3.1) 
(3.2) 
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600 mg of solid polymer was dissolved in 12 ml of solvent and filtered (Whatman filter 
paper) before being filled into the viscometer. Sample concentration was 0.5 g/dL. 
 
3.6 Optical Observation of Microsphere Shrinkage 
 
The formation process of microspheres were tracked with a Nikon polarizing 
microscope (Optiphot 2-pol, Japan) 
 
3.6.1 Initial formation 
The first sample was drawn immediately after injection of the first emulsion into the 
external aqueous phase. For next 30 minutes, photomicrographs of the sample were 
captured continuously at 5-minute intervals. This was taken as the initial formation of 
microspheres. 
 
3.6.2 Continuous formation 
Following this, samples were continuously drawn at 30-minute intervals after the first 30 
minutes throughout the whole dosing period. Photomicrographs were taken for all the 
samples. Microsphere size was analyzed by the built- in ImagePro software.  The mean 
diameter of the microspheres was taken to be the number average of the diameters of the 
particles captured on the computer image for over 300 microspheres.  
 
3.7 Particle Size Distribution 
 
The mean diameter and particle size distribution of the dried microspheres were 
measured using a laser light-scattering particle size analyzer (Coulter LS 230, a 
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microvolume module, Coulter Corporation, USA) after soaking the microspheres in 
an aqueous solution containing Tween 80 (0.1 w/v %).   
 
3.8 Morphological Analysis 
 
A scanning electron microscope (SEM, Model JSM-5310, JEOL, Tokyo, Japan) was 
used to examine the surface and internal morphology of the microspheres. For this 
study, 10 mg of microspheres were embedded into a Lipshaw M1 matrix (Shandon 
Lipshaw Inc, Pittsburgh, USA) under liquid nitrogen and sectioned using a cryostat 
(Leica CM 3050, Leica Instrument Gmbh, Nussloch, Germany). The microspheres 
and their sectioned samples were mounted on metal holders and vacuum-coated with 
a gold layer prior to the examination under SEM. Thickness of the gold layer was 
optimized to prevent the pores on microspheres from being masked out. 
 
3.9 Drug Distribution Within Microspheres 
 
In this study, a Bio-Rad confocal laser scanning microscope (CLSM, MRC 1024, 
England) was used to observe BSA distribution within the microspheres using BSA 
fluorescence [85]. An excitation wavelength of 488 nm and a 522 DF 32 emission 
filter were used, and a Photo Multiplier Tube 2 (Iris: 6, Gain: 1300, low signal) was 
selected. The laser power was 100%. Filter blocks were T2A (560 DRLP) and B1 
(Beam splitter). All the observations were conducted using the same resolution.  
 
3.10 Interactions Between BSA and Polymers 
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A Fourier transform infrared spectrophotometer (FT-IR, Perkin Elmer Spectrum 
2000) was employed to explore the interactions between BSA and various polymers 
using potassium bromide pellets.  
 
3.11 Thermal Analysis 
 
Glass transition temperature (Tg) was measured using a Perkin Elmer 7-series 
differential scanning calorimetry (DSC) (Model DSC 4, Perkin-Elmer, CT, USA) 
with 5-10 mg of the polymeric microspheres. The Tg was determined by first cooling 
the sample from 10 to –10ºC and then heating to 150ºC at a heating rate of 10 ºC/min 
in a nitrogen atmosphere. All the glass transition temperatures were obtained from the 
second heating process. 
 
3.12 Chemical Composition of the Microspheres Surface 
 
An X-ray Photoelectron Spectroscope (XPS) was employed to investigate the 
chemical composition of the microsphere surfaces. The XPS measurements were 
performed using a VG ESCA LAB 220I-XL spectrometer with a magnesium anode 
source producing Mg Ka (1253.6 eV photons) X-ray with the pass energy of 20 eV 
for high-resolution narrow scans and 150 eV for low-resolution wide scans. The XPS 
data analysis was carried out using the software from VG ESCA LAB. To 
compensate for surface charges, all XPS binding energies were referred to the 
adventitious C 1s peak at the binding energy of 285.0 eV. Atomic concentration was 
determined from the peak areas under each peak component and correcting using the 
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manufacturer’s atomic sensitivity factors (ASF) with an estimated maximum error of 
±5%. Spectral curve fitting was performed using the manufacturer-supplied software.  
 
3.13 PEG Content Remained in POE/PEG Blend Microspheres 
After Microspheres Fabrication 
 
Nuclear magnetic resonance spectroscopy (NMR) was utilized to determine the actual 
content of PEG remaining in the microspheres after preparation. 10 mg of 
microspheres were placed into a glass NMR sample tube with 1 ml of deuterated 
chloroform solution. The proton NMR spectra were acquired on a NMR spectrometer 
(Bruker AC 400, Germany). The hydrogen from the methylene group of the PEG 
homopolymer resonated at 3.6 ppm while that of the methylene group from POE 
polymer appeared at 4.2 ppm. The areas under the peaks were integrated to determine 
the ratio of POE to PEG. 
 
3.14 Water Uptake of Microspheres 
 
After incubation in PBS (pH 7.4) for 10 days at 37 °C, microspheres were taken out 
and weighed immediately. The water uptake of microspheres was estimated using 
equation 3.3 as below: 
 
Water uptake (%)= (W1-W2)/W2  ´100%, 
 
where W1 and W2 are the weights of the hydrated microspheres and dried 
microspheres, respectively. 
(3.3) 
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3.15 Primary Emulsion Stability Tests 
 
Stability of the primary emulsion (BSA/PBS droplets dispersed in the 
polymer/methylene chloride solution) was estimated from the de-mixing time. 0.3 ml 
of PBS (containing 70 mg of BSA) was emulsified in 12 ml of methylene chloride 
(containing 600 mg polymer blend) in an assay tube fitted with a stopper. The time 
required for initial macroscopic phase separation to occur was measured at room 
temperature (22 °C). 
 
3.16 In vitro Release Study 
 
In vitro BSA release tests of polymeric microspheres were carried out in triplicate at 
37°C in PBS buffer (pH 7.4). 40 mg of the dried microspheres were suspended in 1 
ml PBS buffer. In vitro medium from each sample was periodically removed and 
replaced with fresh PBS buffer. The BSA content in the in vitro medium was 
analyzed using the HPSEC system as described in Section 3.4 and bicinchoninic acid 
(BCA) protein assay.  
 
3.17 In vitro Weight Loss 
 
170 mg of the dried microspheres were immersed in 5 ml of PBS buffer. The 
supernatant from each sample was removed and replaced with fresh PBS periodically 
parallel to the in vitro release tests. At preset time intervals, samples were separated 
and vacuum-dried to constant weight. Mass loss was examined gravimetrically. 
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3.18 Molecular Weight Distribution 
 
Molecular weights were determined using a gel permeation chromatography (GPC) 
(Waters 2690, MA USA). A 10 mg amount of sample was dissolved in 5 ml of THF 
and the solution was then filtered. The mobile phase was THF at a flow rate of 1 
ml/min. Weight and number average molecular weights were calculated from a 
calibration curve using a series of polystyrene standards (Polymer Laboratories Inc., 
MA USA, with molecular weight ranging from 1350 to 151,700).  
 
3.19 Sodium Dodecyl Sulphate-Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) 
 
The structural integrity of BSA within the degrading microspheres was examined 
under non-reducing conditions using a Bio-Rad Mini-Protean III electrophoresis 
system [86]. Briefly, 0.5 mg of dried microsphere samples were suspended in a Tris-
buffer, pH 6.8, containing 2% SDS for one hour. Then the suspensions were directly 
loaded into the wells with a micropipette. Electrophoresis was performed at 180 V, 
100 mA. The gel was stained with 0.1% Coomassie Brilliant Blue to visualize the 
protein, destained with an aqueous solution of 20% ethanol and 10% acetic acid, then 
dried overnight. 














RESULTS AND DISCUSSION I: 
Protein-Loaded POE-PEG-POE Microspheres 
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The use of poly (ethylene glycol) (PEG) in controlled release systems is receiving 
considerable attention. PEG has several advantages such as high solubility in water 
and organic solvents, biocompatibility, non-toxicity, non-immunogenicity and protein 
resistivity [58-63]. Conjugates of proteins with PEG have proved to be able to provide 
prolonged protein circulation life, reduced immunogenicity and antigenicity [58, 87-
88]. In particular, PEG-adenosine deaminase and PEG-asparaginase are two PEG-
protein conjugates approved by FDA for the treatment of ADA deficiency and acute 
lymphoblastic leukaemia, respectively. In addition, PEG conjugation with anti-tumor 
agents is also of great interest since PEG-anti-tumor agent conjugates could improve 
the water-solubility and stability of such agents, thus eliminating side effects [89]. 
Besides, the use of diblock copolymeric micelles with hydrophilic PEG as the shell, 
for targeted drug delivery, has also been frequently reported [90-93].  
 
Recently, many studies on the use of blends and copolymerization of poly(lactic acid) 
(PLA) or poly(lactic-co-glycolic acid) (PLGA) or poly(butylene terephthalate) with 
PEG for protein delivery have been undertaken [94-97]. Generally, protein release 
from PLA or PLGA microspheres is affected by both protein diffusion through the 
porous matrix, and polymer erosion. This is characterized by a high initial burst 
followed by a lag in release due to slow polymer degradation and an acidic 
environment within the microspheres matrices [98-101]. This becomes a constraint 
for their use in protein delivery. The introduction of PEG in the polymer backbone 
could increase the hydrophilicity of the polymer matrix, and create a swollen 
hydrogel-like environment. Thus, PLA-PEG-PLA or PLGA-PEG-PLGA copolymeric 
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microspheres were tailored to provide a sustained release of protein for a period of 2 
to 3 weeks [101-103]. 
 
The introduction of PEG to POE polymers in our study is expected to improve protein 
encapsulation and its in vitro release pattern. In this section, the fabrication and 
characterization of protein-loaded POE-PEG-POE microspheres are presented, 
followed by the studies of erosion and protein release mechanisms of the 
microspheres. Finally, the optimization of protein release profiles is attempted by 
varying fabrication conditions and polymer compositions.  
 
4.1 Fabrication And Characterization of Protein-loaded POE-
PEG-POE Microspheres 
 
In this part, I focus on the first objective of my research work, which is to prepare and 
characterize protein-loaded POE-PEG-POE microspheres. In particular, the effects of 
PEG content in the triblock copolymer, salt and emulsifier concentration in the 
external water phase, protein loading as well as polymer concentration on size 
distribution, morphology and protein encapsulation efficiency, are studied.  
 
4.1.1 Effect of PEG Content  
4.1.1.1 Microspheres Formation Process 
 
Microsphere formation is a very complicated chemical engineering process. Similar 
to the fabrication of hollow fiber membranes, the formation of microspheres can be 
divided into three stages: (1) droplet formation, (2) solvent removal and solidification 
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and (3) washing and drying (Figure 2.11). Among these stages, solvent removal and 
solidification process may be the dominant stage to determine morphology and 
release characteristics of microspheres. Jeyanthi et al. [104] reported that the dilution 
solvent-removal technique yielded microspheres with a uniform honeycomb-like 
matrix with pore sizes depending on the extent of continuous water-phase dilution. 
They found that the higher the extent of continuous water phase dilution (to form the 
second emulsion) and the higher continuous water phase addition (to form the nascent 
microspheres), the larger the pores. 
 
We used POE-PEG(5%)-POE microspheres as an example to demonstrate the details 
of microspheres formation process (Figure 4.1). At predetermined time intervals, a 
certain amount of aqueous solution was taken out and observed under an optical 
microscope. The monitoring started 5 minutes after the first emulsion was injected to 
the continuous water phase. Figure 4.1 shows that the microspheres were extremely 
soft even after 10 minutes. At this stage, the microspheres were transparent, with 
small water droplets evenly distributed inside. The pores formed within the 
microspheres after vacuum drying are attributed to these small internal water droplets. 
Since BSA is water-soluble and dissolved in the internal water phase, it is believed 
the protein particles usually distribute around the wall of internal pores. Therefore, the 
distribution and the size of pores will have significant influence on the protein release. 
10 min later, the nascent microspheres appeared to be black, indicating that the 
particles hardened because most of the solvent has been removed.  
 
The magnified images showing the formation of internal pores are presented in Figure 
4.2. The hardening process was completed within 30 minutes, suggesting that most of 
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the solvent might have been removed. This result is coherent with the data of particle 
size changes during the fabrication process, which will be reported later. 
 
During the microspheres formation process, water was added to the double emulsion 
with a speed of 3 ml/min. The purpose for adding water is to facilitate the extraction 
of solvent and to further solidify the microspheres [104].  Properties of microspheres 
could be altered by varying the rate of water addition. Y. Y. Yang et al. [4, 79, 84] 
reported a higher water addition rate led to more rapid skin solidification, hindering 
the migration of BSA outwards the surface of microspheres. Thus, the protein 
encapsulation efficiency was increased. If the addition speed increased too fast, the 
encapsulation efficiency dropped. This is because at higher water addition speeds, 
faster mass transfer occurred. Meanwhile, the increase in the rate of water addition 
also caused dissolution of more drug molecules from the interior of microspheres to 
the continuous water phase, leading to the decrease of encapsulation efficiency [84]. 
Thus the water addition rate should be finely tuned. The speed of 3.0 ml/min was 
chosen in my research because it was found that the drug initial burst and 
encapsulation efficiency could be well optimized at this adding rate. 
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4.1.1.2 Changes in Microspheres Size During the Formation Process 
 
The POE-PEG-POE microspheres were fabricated using the double emulsion solvent 
evaporation/extraction process described in Chapter 2. The microspheres shrinkage 
during the formation process was observed under a polarizing microscope starting at 
5 minutes after the first emulsion was injected into the continuous phase. Changes in 
diameter of the nascent microspheres during a double emulsion fabrication process 
are influenced by such factors as solvent removal, water uptake and polymer 
dissolution. Figure 4.3 shows typical patterns on the diameter of the microspheres 
made from POE-PEG(5%)-POE and POE-PEG(30%)-POE copolymers as a function 
of processing time. The diameter of the microspheres decreased but reached a 
relatively constant level after 30 minutes. On the other hand, the microspheres made 
from POE-PEG(5%)-POE and POE-PEG(10%)-POE under the microscope were dark 
and solid after 30 minutes due to removal of the solvent (methylene chloride) and 
























1. POE-PEG(5%)-POE   2. POE-PEG(30%)-POE 
Figure 4.3 Diameter change during the microspheres formation. 
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transparent until the end of the fabrication process, resulting from swelling of the 
polymer that hindered microspheres solidification.  
 
The average sizes of the microspheres made from POE-PEG(5%)-POE, POE-
PEG(10%)-POE, POE-PEG(20%)-POE and POE-PEG(30%)-POE before and after 
vacuum drying are shown in Table 4.1, which were measured by a laser light-
scattering particle size analyzer. Individual POE-PEG(30%)-POE microspheres were 
not obtained due to aggregation after vacuum drying. Generally, viscosity of a 
polymer solution has a significant effect on size of the resultant microparticles. The 
more viscous the polymer solution, the more difficult to be broken down into smaller 
droplets, leading to bigger microparticles [84]. POE-PEG(5%)-POE solution had a 
similar viscosity to POE-PEG(10%)-POE one (Table 4.1). Thus, the mean diameters 
of the resultant microspheres were quite close. However, POE-PEG(20%)-POE 
yielded much bigger microspheres than POE-PEG(30%)-POE even though there was 
no sharp difference in viscosity between these two polymer solutions. In addition, it 
can also be seen from Table 4.1 that the mean size of POE-PEG(20%)-POE 
microspheres dropped to 75.0 µm from 121.1 µm after vacuum drying but it did not 
change very much for POE-PEG(5%)-POE or POE-PEG(10%)-POE microspheres. 
This is due to the fact that POE-PEG(20%)-POE microspheres with a higher PEG 
content suffered more significant swelling. PEG had two effects on microspheres. 
The presence of hydrophilic PEG blocks in the copolymers might cause swelling of 
the microspheres but it might also lead to the dissolution loss of microspheres into the 
external water phase. Dissolution loss effect might be dominant for the POE-
PEG(30%)-POE polymer. As a result, POE-PEG(30%)-POE yielded much smaller 
microspheres.  
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4.1.1.3 Surface and Internal Morphology 
 
The surface morphologies of microspheres were examined using SEM. Figure 4.4 
shows that POE-PEG(5%)-POE, POE-PEG(10%)-POE and POE-PEG(20%)-POE 
yielded spherical microparticles. POE-PEG(30%)-POE microspheres were well 
dispersed while in the external water phase, but they formed aggregates after filtration 
and vacuum drying (Figure 4.4). In addition, SEM micrographs using high 
magnifications show that the surface became rougher with an increase in PEG content 
in the copolymers. A possible explanation is that microspheres with high PEG 
contents were in a highly swollen state and the skins collapsed after vacuum drying. 
This phenomenon was also observed in PBT-PEG and PLGA-PEG-PLGA 
microspheres [105, 106]. Quellec et al. reported [107] that PLA-PEG diblock 
copolymer yielded a PEG “brush” on the resultant nanospheres since PEG chains 
oriented to the external water surface during the formation process. The density of the 
PEG “brush” decreased with protein entrapment. The surface of POE-PEG-POE 
microspheres was also analyzed using XPS. Table 4.2 lists the chemical compositions 
of the microspheres surface. No nitrogen atoms were detected. Since nitrogen atoms 
were only present in BSA, this indicates that BSA was well entrapped within the 
microspheres matrices. Figure 4.5d shows the XPS high-resolution scans of 
microspheres surfaces. The largest peak at the lowest binding energy was indicative 
of alkane carbon (C-C) or C-H, and the smaller, intermediate peak was the C-O peak. 
The small, highest energy peak was due to the presence of carbon-oxygen double 
bond (C=O) on the surface. The peak of carbon-oxygen double bond came from POE 
due to the absence of BSA on the surface. In addition, from Table 4.3, we see that 
there was no sharp difference in the C=O content between the polymers and the 
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microspheres. Thus, these findings enabled us to presume that the POE-PEG-POE 
copolymers used in this study did not yield PEG-coated microspheres. Possibly, this 
was due to the spatial hindrance of triblock copolymer molecules. Also, it is observed 
that there was no BSA on the surface of microspheres since we could not detect the N 
atom in the wide scan (Figure 4.5a, 4.5b and 4.5c) while N was present in all the 
protein structures. The results were understandable because the hydrophilic protein 
should have been dissolved into the continuous water phase during the second 
emulsion process. The BSA amount on the microspheres surface was too little to be 
detected. 
 
Figure 4.6 shows cross-section SEM micrographs of POE and POE-PEG-POE 
microspheres. Neat POE microspheres show a multivascular internal structure that 
resulted from an unstable first emulsion. POE is a highly hydrophobic polymer and 
the affinity between POE and BSA was weak. As a result, the first emulsion of 
POE/methylene chloride and BSA/PBS was extremely unstable, we observed that it 
separated into two phases within 1 min after sonication. During the microspheres 
formation process, the internal water droplets coalesced easily in a very hydrophobic 
environment and resulted in the multivascular structure characterised by a thick and 
dense wall with poor inter-pore connections (Figure 4.6 and 4.7). The attachment of 
PEG blocks to the POE polymer increased the polymer hydrophilicity, which 
stabilized the first emulsion. Thus POE-PEG-POE yielded the microspheres with a 
uniform pore distribution. On the other hand, from the micrographs shown in Figure 
4.4, we also observe that with an increase in PEG content, the cross-section images of 
POE-PEG-POE microspheres show a denser internal structure. This might be due to 
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the fact that an increased PEG content allowed fine dispersion of internal water in the 
polymer matrix, which resulted in an apparently denser structure after drying.  
Figure 4.4 Surface SEM scans of POE-PEG-POE microspheres with different 
PEG contents. A1, B1, C1, D1 represents 5%, 10%, 20% and 30%, respectively. Size 
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POE-PEG(5%)-POE copolymer 2.86:1:0 
POE-PEG(10%)-POE copolymer 3.00:1:0 
POE-PEG(20%)-POE copolymer 2.99:1:0 
POE-PEG(5%)-POE microspheres 2.86:1:0 
POE-PEG(10%)-POE microspheres 2.92:1:0 
POE-PEG(20%)-POE microspheres 2.65:1:0 
 
Table 4.2 Atomic ratio of carbon and oxygen on the surface of samples. 
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4.1.1.4 Encapsulation Efficiency 
 
A double emulsion process is the most common method used to encapsulate 
hydrophilic drugs especially proteins. The encapsulation efficiency of a drug depends 
on its solubility in water, the affinity between the drug and polymer, and the 
microspheres’ formation process. As listed in Table 4.4, neat POE yielded 31.7% of 




Figure 4.6 Cross-sectional SEM scans of POE-PEG-POE microspheres with 
different PEG contents. (a) POE (b) POE-PEG(5%)-POE (c) POE-PEG(10%)-
POE (d) POE-PEG(20%)-POE. Size of the bar is 10 µm. 
(a) 
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into the POE polymer chains, an encapsulation efficiency of up to 94% was achieved. 
There were two possible reasons. First, the affinity between BSA and the polymer 
increased due to the presence of the hydrophilic PEG blocks in the polymer chain. 
Second, as discussed previously, POE-PEG-POE provided a more stable first 
emulsion so that BSA was well entrapped and dispersed within the resultant 
microspheres. We did the demixing tests to observe the stability of the primary 
emulsion. The data were presented in Figure 4.8. Comparing to copolymeric 
microspheres, the demixing time of primary emulsion for pure POE microspheres was 
much faster. It suggested the more stable first emulsion of copolymers. Interestingly, 
we also observed there was little difference in the demixing time among the four first 
emulsions. 5% PEG might be enough to stabilize the first emulsion. The results are 
consistent with those of BSA encapsulation efficiency. The encapsulation efficiency 



































Figure 4.8 First emulsion demixing time of POE and POE-PEG-POE 
microspheres with various PEG contents. 
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The CLSM images shown in Figure 4.9, where bright colour represented BSA, further 
confirm that POE-PEG-POE triblock copolymers yielded uniform BSA distribution. 
In this study, we attempted to use FTIR to investigate the interactions between BSA 
and the triblock copolymers. Figure 4.10 shows the infrared spectra of BSA, POE-
PEG(20%)-POE and BSA-loaded POE-PEG(20%)-POE microspheres. The spectrum 
of POE-PEG(20%)-POE (Figure 4.10a) shows a carbonyl band at 1741 cm-1 and an 
amide carbonyl band from BSA appears at 1654 cm-1 (Figure 4.10b). From the 
spectrum of the BSA-loaded microspheres (Figure 4.10c), we observe that there are 
no significant shifts in these two bands. The same phenomena were observed with 
POE-PEG(5%)-POE and POE-PEG(10%)-POE. The results suggested the absence of 
strong chemical interactions between BSA and POE and the physico-chemical 
integrity of BSA was retained within the microspheres.  
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Figure 4.9 CLSM images of POE-PEG-POE microspheres with different PEG 
contents. (a) POE-PEG(5%)-POE, (b) POE-PEG(10%)-POE, (c) POE-PEG(20%)-POE. 
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4.1.2 Effect of Salt Concentration in the External Water Phase 
 
Thompson et. al. reported the encapsulation of porcine rismorelin, a highly water-
soluble hormone, within PLGA microspheres using PBS as the external water phase 
[108]. It was also suggested that the encapsulation efficiency of an outer membrane 
protein (OMP) within PLA-PEG microspheres could be increased from 48.2% to 
65.4% when 20% NaCl was added to the external water phase [109]. In this study, we 
used PBS, diluted PBS (half of its original concentration with DI water), and DI water 
as the external water phases to investigate salt effects. Interestingly, unlike the 
previous work, DI water yielded slightly higher BSA encapsulation efficiency 
(93.4%) when compared to encapsulations using salt (91.9%, 88.1% for PBS and the 
diluted PBS, respectively). This was probably attributed to the morphology of the 
resultant microspheres. The surface morphology was not affected by the external 
water phases (Figure 4.11). However, from the cross-section SEM images shown in 
Figure 4.11, we observe that the microspheres with dense walls were produced when 
half-diluted PBS and DI water were employed as the external water phase. This might 
be a consequence of a faster solvent removal in DI water and water solution with low 
salt concentrations. Actually, the presence of salt reduced the solubility of methylene 
chloride in water. As a result, the polymer precipitated more rapidly in water phase 
with the low salt concentration or DI water than in PBS solutions. As shown 
previously, nascent microspheres hardened during the first 30 minutes in PBS (Figure 
4.2), whereas they were still transparent at 60 minutes in DI water as shown in Figure 
4.12. Apparently, the polymer precipitated in DI water and half-diluted PBS formed 
tighter and denser skins, which hindered the exchange of methylene chloride with the 
surrounding medium. 























Figure 4.11 Surface and cross-sectional SEM scans of POE-PEG(5%)-
POE microspheres using (a) PBS (b) Half-diluted PBS (c)  DI water as the 
external aqueous phase. Size of the bar is 10 µm. 
(c)
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4.1.3 Effect of Drug Loading 
 
To investigate the effect of BSA loading on properties of microspheres, loading was 
varied from 5%, 15% to 20%. Figure 4.13a shows size distribution of the resultant 
microspheres. An increased BSA loading led to larger microspheres because it was 
more difficult for the more viscous first emulsion to break down into smaller droplets. 
For microspheres with a thick wall, similar results were observed (Figure 4.13b). 
From Table 4.5, there was no sharp difference in BSA encapsulation efficiency. This 
was due to the stable first emulsion and the good affinity between BSA and POE-
PEG(5%)-POE that prevented BSA from loss to the external water phase during the 














Figure 4.13a Particle size distribution of POE-PEG(5%)-POE 
microspheres with 5%, 15% and 20% of BSA loadings. The mean diameter is 
expressed as volume diameter. 
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4.1.4 Effect of PVA Concentration in the External Aqueous Phase  
 
It is well known that particle size can be controlled by varying the emulsifier 
concentration in the external water phase [110, 111]. As shown in Figure 4.14, an 
increased PVA concentration led to a slight decrease in particle size. PVA 
concentration had an offsetting effect on size of microspheres. Since PVA is a 
polymer with a high molecular weight, the presence of PVA in the external water 
phase might increase the viscosity of the double emulsion, resulting in an increased 
difficulty in breaking up the emulsion into smaller droplets. Thus, this yielded bigger 
microspheres. On the other hand, the presence of PVA in the external water phase 
stabilized emulsion droplets against coalescence, resulting in smaller emulsion 
droplets. In our present work, it can be concluded that the stabilization effect was 
dominant at higher PVA concentrations and led to the decrease in the size of 
Figure 4.13b Particle size distribution of POE-PEG(5%)-POE microspheres 
with 5%, 10% and 20% of BSA loadings. The mean diameter is expressed as 
volume diameter. (DI water as the external aqueous phase) 
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microspheres. Table 4.6 indicates that there was no considerable effect on the BSA 
encapsulation efficiency because of the good affinity between BSA and POE-PEG-
POE copolymers as discussed previously. In addition, there was no obvious difference 
in terms of surface and internal morphologies of microspheres fabricated with 



















Figure 4.14 Particle size distribution of POE-PEG(10%)-POE 
microspheres with 0.05%, 0.5% or 2.0% of PVA concentration in the 
external water phase. 
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Figure 4.15 Surface and cross-sectional SEM scans of POE-PEG(10%)-POE 
microspheres using different emulsifier concentrations in the external water phase. A, B, 
C represents 0.05%, 0.5% and 2.0% PVA, respectively. Size of the bar is 10 um. 
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4.1.5 Effect of Polymer Concentration 
 
Figure 4.16 shows particle size distribution of microspheres fabricated with various 
polymer concentrations. Clearly, the polymer concentration played a greater impact 
on particle size than the PVA concentration described above. When the polymer 
concentration decreased from 50.0 mg/ml to 16.7 mg/ml, the average size of POE-
PEG(10%)-POE microspheres dropped to 53.2 µm from 76.5 µm due to the decrease 
in viscosity of polymer solution. As shown in Table 4.7, the polymer concentration 
did not affect the encapsulation efficiency much owing to the good affinity between 
BSA and the polymer. However, from Figure 4.17, a reduced polymer concentration 
produced microspheres with more porous surface and internal structures. This might 
be due to two factors: (1) the internal water droplets in the low polymer concentration 
solution tended to coalesce together more easily, leading to bigger pores and a less 
tortuous network, (2) the higher polymer concentration solution coagulates faster 
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Figure 4.16 Particle size distribution of POE-PEG(10%)-POE 
microspheres with 16.7, 33.3 or 50.0mg/ml of polymer concentration.







Figure 4.17  Surface and cross-sectional SEM scans of POE-PEG(10%)-POE 
microspheres with different polymer concentrations in the organic phase. A, B, C 
represents 16.7, 33.3 and 50.0mg/ml of polymer concentration, respectively. Size of 
the bar is 10 µm. 
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4.2 Erosion and Protein Release Mechanisms of POE-PEG-
POE Microspheres 
 
In this part, I focus on the second objective of my research work, which is to 
investigate polymer erosion and protein release mechanisms of POE and POE-PEG-
POE microspheres. Essentially, the microspheres surface and internal morphologies 
during the in vitro degradation, the polymer degradation rate, as well as the protein 
release profiles were thoroughly studied. 
 
4.2.1 Morphologies of Degrading Microspheres 
 
It was frequently reported that polyesters underwent bulk erosion mechanism and the 
microparticles degradation occurred in a heterogeneous manner [112]. In this case, the 
polyester breakdown products accumulated within the microparticles, leading to more 
rapid degradation in the center. Hence, such microparticles appeared less spherical 
with increased polymer degradation [7, 112]. Figure 4.18 illustrates surface SEM 
micrographs of POE-PEG-POE microspheres after incubation in PBS buffer at pH 7.4 
for 14 weeks. Unlike polyester microparticles, POE-PEG-POE microparticles became 
smaller, but remained spherical even after exposure to PBS buffer for such a long 
period of time. The surfaces became rougher with the progression of polymer 
degradation (Figures 4.19, 4.20 and 4.21). The internal morphology of POE-PEG 














Figure 4.18 SEM scans of POE-PEG-POE microspheres after incubation in PBS 
buffer, pH 7.4, 37°C for 14 weeks: (A) POE-PEG(5%)-POE, (B) POE-PEG(10%)-POE 
(C) POE-PEG(20%)-POE. Size of the bar is 100 µm. 





Figure 4.19 SEM scans of POE-PEG(5%)-POE microspheres before (A) and 
after (B) 4-week (C) 14-week in vitro release.  Size of the bar is 10 µm. 





Figure 4.20 SEM scans of POE-PEG(10%)-POE microspheres before (A) 
and after (B) 4-week (C) 14-week in vitro release. Size of the bar is 10 µm. 






Figure 4.21 SEM scans of POE-PEG(20%)-POE microspheres before (A) 
and after (B) 4-week (C) 14-week in vitro release. Size of the bar is 10 µm. 
 






Figure 4.22 Internal morphology of POE-PEG(5%)-POE microspheres (DI 
water as the external aqueous phase)  before and after in vitro release. Size of 
the bar is 10 µm. 
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(Figure 4.21). On the other hand, POE-PEG (5%)-POE and POE-PEG (10%)-POE 
microspheres appeared to become denser due to the decrease in internal pore sizes 
(Figures 4.19 and 4.20). This possibly arises from the swell of the internal matrix 
because of the hydrophilic PEG segments and the loss of mechanical strength in the 
degrading microspheres, which might have led to the collapse of the internal porous 
structure during the vacuum drying process. Figure 4.22 in particular reveals that with 
increasing polymer degradation, the dense boundary of the microsphere surface 
became thinner. The findings suggest that the microspheres eroded from the surface 
towards the center. 
 
4.2.2 Microspheres Water Uptake and Swelling 
 
PEG is highly water-soluble. Thus, it was observed that PLGA-PEG-PLGA 
copolymers swelled to varying degrees depending on the PEG content [103]. Results 
of water uptake for POE and POE-PEG-POE microspheres are shown in Figure 4.23. 
Clearly, the water content within microspheres tended to increase with the increasing 
of PEG content. Table 4.8 demonstrates the significant swelling observed with POE-
PEG (20%)-POE microspheres. The mean diameter of the microspheres increased 
from 90 µm to 164 µm after incubation for two days in PBS buffer. It subsequently 
decreased gradually and reached 93 µm on Day 14 mainly because of polymer 
degradation as well as the nature of densification. In contrast, POE-PEG (5%)-POE 
and POE-PEG (10%)-POE microspheres did not swell so much due to the relatively 
low PEG content. The microspheres underwent decreases in mean diameter of 11 and 
14 µm, respectively, during the first two weeks. Thus, the swelling properties of the 
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microspheres made from each POE-PEG-POE polymer appeared to affect its rate of 
degradation and protein release mechanism as discussed below. 


































































4.2.3 pH Changes as A Function of Incubation Time 
 
The acidity change of the release media during the in vitro process was monitored to 
investigate polymer degradation.  Figure 4.24 shows that there was a higher pH drop 
especially for POE-PEG (5%)-POE and POE-PEG (10%)-POE during the first week 
Table 4.8  Volume mean diameters (µm) of degrading microspheres 
Figure 4.23  Water uptake of POE and POE-PEG-POE microspheres after 7-
day incubation in PBS at 37°C.  
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in vitro. Thereafter, the pH change was too little to be detected. POE employed in this 
study contains latent acids. After hydrolysis, acidic products were created. The higher 
pH drop indicated faster degradation at the initial stage. From Figure 4.24, it can also 
be seen that the degradation of POE-PEG (5%)-POE and POE-PEG (10%)-POE was 
faster than that of POE-PEG (20%)-POE during the initial stage of in vitro tests. This 
is consistent with the trend of molecular weight change and weight loss for the 
















4.2.4 Molecular Weight Changes And Weight Loss 
 
The changes in weight, and molecular weight of the microspheres were monitored as 
a function of incubation time. From Figure 4.25, it can be seen that the POE-PEG 
(5%)-POE and POE-PEG(10%)-POE microspheres displayed a biphasic degradation 
pattern, which was characterized by a high initial decrease during the first two weeks, 
Figure 4.24 pH changes as a function of incubation time. 
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with subsequently much slower molecular weight loss for 12 weeks. However, the 
POE-PEG (20%)-POE microspheres possessed a rather constant molecular weight 
during degradation (Figure 4.25). For instance, during the first two weeks, weight 
molecular weight of the POE-PEG (5%)-POE, POE-PEG (10%)-POE and POE-PEG 
(20%)-POE microspheres lost 38%, 44% and 27%, respectively. From Week 2 to 
Week 14, an almost identical weight molecular weight loss ranging from 35% to 38% 
occurred in all three kinds of microspheres. Not surprisingly, changes in 
polydispersity index for all the triblock copolymers also followed up a similar trend 












Figure 4.25 Weight average molecular weight (Mw) changes of POE-
PEG-POE microspheres as a function of incubation time. 































Figure 4.27 Weight loss of POE-PEG-POE microspheres as a function of 
incubation time. 
Figure 4.26 Polydispersity index of POE-PEG-POE microspheres as a 
function of incubation time. 
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According to Li et al. [114], there were three phases in the LPLA-PEG-LPLA 
polymer system when immersed in an aqueous phase: a glassy and hydrophobic 
LPLA phase with lowest water content, a swollen PEG phase with highest water 
content and a phase consisting of LPLA and PEG with a higher water content than the 
LPLA phase. Like LPLA-PEG-LPLA, POE-PEG-POE contains highly hydrophobic 
POE (CDM/TEG/TEG-diGL: 94:5:1) and hydrophilic PEG segments. When 
incubated in the PBS buffer, water penetrated through the microspheres matrix and 
preferentially stayed in PEG domains via hydration. Due to the microphase 
separation, the cleavage of POE-PEG-POE polymer occurred predominantly in the 
phase of POE and PEG. The triblock polymers degraded most likely between the PEG 
and POE blocks. Thus, preferential PEG loss from the microsphere matrix might 
attribute to a rapid initial degradation and weight loss.  
 
The glass transition temperature (Tg) of polymeric microspheres was also monitored. 
Tg of POE-PEG (5%)-POE degrading microspheres is presented in Figure 4.28. Tg of 
both polymer and microspheres are very close (79.5 °C for polymer and 79.4 °C for 
microspheres), reflecting the microspheres fabrication process did not alter the length 
of polymer chain. Tg of the microspheres decreased to 74.9 and 68.0 °C after 2 and 4 
weeks in vitro, respectively. The decrease of Tg resulted from the degradation of 
polymer and protein release. Protein release might leave some space, making the 
polymer chain more flexible and leading to lower Tg.  
 
Interestingly, we also observe from Figure 4.25 that molecular weight decrease of the 
triblock copolymers with less PEG contents was faster. Possibly, the triblock 
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copolymers with lower PEG contents of 5% and 10% in weight yielded a less phase 
compatibility, which might enable the ester-bonds in the vicinity of the POE/PEG 
interface to break down more easily. From Figure 4.27, we observe a higher initial 
weight loss ranging from 47% to 52% during the first two weeks for the copolymers 
with low PEG contents. However, these two POE-PEG-POE copolymers only contain 
5% and 10% PEG in weight, respectively. If loss of the PEG segments in the polymer  
backbone and the protein released mainly accounted for this initial weight reduction, 
the maximum loss in mass should not be more than 20%. Therefore, it enabled us to 
assume that a less phase compatibility of the copolymers with low PEG contents also 
promoted degradation of the POE blocks, resulting in a higher initial decrease in mass 
and molecular weight. In addition, more porous internal structure might be another 
reason for a faster initial degradation in POE-PEG (5%)-POE and POE-PEG(10%)-
POE microspheres. From Figure 4.25, it can also be seen that the molecular weight 
remained rather constant with these two copolymers for 12 weeks after the initial 
degradation, but mass loss was continuous up to a range from 89% to 92% at Week 
14. This arises most likely from POE erosion properties. The mechanism of POE 
microspheres erosion has been extensively studied in our laboratory. The results 
showed that POE microspheres eroded on surfaces including both internal and 
external ones that were in contact with water. There were no significant changes in 
molecular weight during 129-day in vitro tests. However, the mass loss patterns were 
fairly continuous and linear. In addition, during the 129-day degradation, glass 
transition temperatures (Tg) of the polymers were staying constant [115]. It is 
postulated that the chain length and composition of the degrading POE polymers are 
similar to the original non-degraded polymers. In contrast, polyesters yielded a 
different degradation profile in which molecular weight decrease was faster than mass  
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loss [115] since the degradation products were not small enough to dissolve or could 
not move out into the buffer. Thus, the degradation acids auto-catalysed polymer 
degradation, leading to a well-known bulk erosion mechanism.  
 
From the experimental results presented above, at a content of 20% PEG blocks in 
weight, the POE-PEG-POE copolymer had a better phase compatibility and led to a 
steady and continuous decrease in mass during in vitro degradation. On the other 
hand, molecular weight and polydispersity index were fairly constant during the 14-
week in vitro tests. Similarly, Li Y et al presented [102] that poly (L-lactide) (LPLA)-
PEG- poly (L-lactide) (LPLA) yielded biphasic profiles in molecular weight decrease 
and weight loss. The first phase was caused by PEG loss and LPLA degradation was 
reflected in the second phase. However, poly (L-lactide-co-glycolide) (LPLG) and 
PEG blocks had a better micro-phase compatibility and thus LPLG-PEG-LPLG 
polymer underwent an accelerated degradation. The degradation was not dominated 
by PEG loss but by a loss of both PEG and LPLG blocks.  
 
4.2.5 BSA Release Mechanism 
 
Figures 4.29 and 4.30 display BSA in vitro release patterns from the microspheres 
made from POE and POE-PEG-POE polymers, respectively. It clarifies that compared 
to some other polymers such as polyesters [110] [113] [114], the BSA initial bursts 
were well controlled by POE and POE-PEG-POE polymers. POE microspheres 
yielded a BSA release platform over ten days (Figure 4.29). This might be due to both 
the polymer hydrophobicity nature and the internal structure with a thick and dense 
wall. Normally, it needs longer time for water to penetrate through more hydrophobic  


















































Figure 4.30 Release profiles of POE-PEG-POE microspheres. 
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polymer matrix or across the thick wall to let BSA diffuse out. From the curves in 
Figure 4.30, we also observe that BSA release rate increased when PEG content 
increased from 5% to 10%. But it decreased when PEG content continuously 
increased to 20%. The presence of PEG promoted water penetration, which should 
result in a rapid BSA release. However, a slower BSA release was obtained from the 
POE-PEG (20%)-POE microspheres with a higher PEG content. This is probably due 
to their dense structure.  
 
As presented in previous paragraphs, the POE-PEG (5%)-POE and POE-PEG(10%)-
POE microspheres lost 38% and 44% in mass, respectively, during the first two 
weeks. In addition, both the POE-PEG (5%)-POE and POE-PEG (10%)-POE 
microspheres did not show significant swelling. It can be seen from Figure 4.30 that 
29 and 40% BSA are released out from the POE-PEG (5%)-POE and POE-PEG 
(10%)-POE microspheres, respectively, during the initial stage. Here, effect of BSA 
loading, porosity and size of microspheres was investigated to understand the BSA 
release mechanism. Figure 4.31 indicates BSA release patterns from the POE-PEG 
(5%)-POE microspheres fabricated at different loadings. With an increase in the BSA 
loading, a high BSA release rate was achieved resulting from a high driving force for 
BSA diffusion. A similar result was observed for POE-PEG (5%)-POE microspheres 
with walls (Figure 4.32). Figure 4.33 compares BSA release of the microspheres with 
the wall with those without wall. It was found that the presence of wall did prevent 
BSA release. As reported in the previous paper [115], POE-PEG (10%)-POE 
microspheres with various sizes and internal morphologies were produced at different 
polymer concentrations. Lower polymer concentrations yielded more porous and 
smaller microspheres. This enabled BSA to diffuse out faster (Figure 4.34). For 
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instance, during the first two weeks, 50%, 37% and 28% BSA was released out from 
the microspheres prepared at 16.7%, 33.3% and 50.0% polymer concentrations, 
respectively. Thus, we suggest that BSA release mechanism from the microspheres 
made from the POE-PEG (5%)-POE or POE-PEG (10%)-POE copolymers was based 
on both diffusion and erosion. 






















Figure 4.31 Release profiles of POE-PEG (5%)-POE microspheres 


















Figure 4.32 Release profiles of POE-PEG (5%)-POE 
microspheres with various BSA loadings.(DI water as the external 
aqueous phase) 


























Figure 4.34 Release profiles of POE-PEG (10%)-POE 
microspheres with various polymer concentrations. 
Figure 4.33 Release profiles of POE-PEG (5%)-POE microspheres. 






















PBS Half-diluted PBS DI water
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The triblock copolymer with 20% PEG in weight swelled drastically after incubated 
in the PBS buffer. During the first two weeks, 29% BSA release was accompanied 
with 22% polymer mass loss (Figures 4.27 and 4.30). Figure 4.35 displays the effect 
of BSA loading level on release profiles from POE-PEG(20%)-POE microspheres. It 
shows linear BSA release profiles. BSA release rate increased with an increase in 
loading level. Nearly 70% BSA was released during the first two weeks with a 20% 
loading. Obviously, swelling, erosion and diffusion contributed to BSA release from 




From Figure 4.30, we also observe a non-release and incomplete release of BSA 
encapsulated within the POE-PEG-POE microspheres. During the first initial phase, 
29-40% intact BSA release was confirmed with both HPLC and BCA analysis. No 
further BSA was detected in the in vitro medium up to Week 14 using both two 
methods although the microspheres underwent 86% to 92% weight loss. The protein 























Figure 4.35 Release profiles of POE-PEG(20%)-POE microspheres with 
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PEG-PLA (PLGA) copolymers containing proteins [84, 101, 117, 118]. This may be 
due to either protein aggregation or non-specific adsorption onto the surfaces of 
degrading microspheres [119]. Morlock M et al. [118] demonstrated an erythropoietin 
non-release phase with the microspheres made from poly(lactide-co-glycolide) 
(PLGA)-PEG-poly(lactide-co-glycolide) (PLGA) triblock copolymers containing 7-
32% PEG after a 15-20% first-day burst. However, the copolymer with 46% PEG 
showed a 17% first-day burst followed by a continuous release to 13% erythropoietin 
up to Day 22. Crotts G et al. [86] investigated BSA stability using SDS-PAGE 
analysis and suggested that BSA was covalently aggregated within PLGA 
microspheres during polymer degradation and non-specific BSA adsorption onto 
polymer surface was a critical parameter to influence protein release rates. 
 
In our research, confocal microscope was utilized to detect the BSA presence within 
microspheres after release (Figure 4.36). The images illustrate BSA was still present 
within POE-PEG (5%)-POE microspheres after 14 weeks in vitro. In addition, BSA 
was also detected with POE-PEG (10% and 20%)-POE microspheres using FTIR 
(Figure 4.37).  The carbonyl band from the polymer, amide carbonyl as well as 
carboanion bands from BSA did not shift significantly. No new bands appeared 
during the degradation process. Besides, BSA was detected in the microspheres even 
after 14-week in vitro degradation. Similar results were also observed with the POE-
PEG (5%)-POE and POE-PEG (10%)-POE microspheres. Table 4.9 lists the chemical 
compositions of the degrading microsphere surface. A BSA molecule contains a 
number of nitrogen atoms. No nitrogen atoms were found on the surface of the 
degrading microspheres before Week 2. However, it was detectable after 4-week 
degradation and the percentage of nitrogen atoms slightly increased as a function of 
                                                                                          Chapter 4   Results and Discussions 1 
 119
degradation time. With microspheres degradation, surface area enlarged, which might 




Samples C% O% N%
Before release 72.6 27.4 0.0
After 2-week 76.1 23.9 0.0
After 4-week 74.4 23.3 2.3
After 6-week 74.5 23.0 2.5
After 8-week 74.0 21.9 4.2
After 10-week 73.0 21.4 5.6
Table 4.9 Atomic percentage of elements on the surface of degrading POE-
PEG (20%)-POE microspheres 
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Non-reducing SDS-PAGE of BSA within POE-PEG-POE microspheres was 
performed to investigate BSA structural integrity. Under non-reduced conditions, all 
aggregates linked by disulfide bonds should remain. Figure 4.38 displays non-
reducing SDS-PAGE results of standard BSA and BSA within the degrading 
microspheres. Faint BSA bands in response to the microspheres before release was 
observed due to presence of a dense skin layer that hindered BSA migration from the 
microspheres to the gel. From Figure 4.38, it can be seen that stained bands 
representing molecular weight of BSA monomer, dimmer and higher order aggregates 
existed in both the BSA standard and BSA within the degrading microspheres. It was 
reported that the double emulsion process could cause the formation of protein 
aggregates [86, 120]. There was no degradation during the first 8 weeks of incubation 
but BSA degradation bands appeared after 10 weeks. This suggests that the POE-
PEG-POE copolymeric microspheres provided BSA a friendly environment in the in 
vitro medium at 37 °C at least for 8 weeks. POE blocks used in this study contain 
94% rigid trans-cyclohexanedimethanol (CDM) and the microspheres degraded 
slowly after most PEG blocks left from the chains of POE-PEG (5%)-POE and POE-
PEG (10%)-POE polymers. Thus, it is assumed that prior to degradation, non-release 
was attributed to slow polymer degradation. As for POE-PEG (20%)-POE 
microspheres, low degradation rate came from their dense structure. Slow release led 
to low BSA concentrations in the in vitro medium, which were not detectable by both 















9 7 8642 3 51 
Figure 4.38 Non-reducing SDS-PAGE results of BSA within POE-PEG(5%)-
POE microspheres suspended in gel loading buffer. Lane 1, protein molecular 
weight markers; lane 2, BSA control; lane 3, the microspheres before release; 




                                                                                   Chapter 4   Results and Discussions 1 
 124
4.3 Modulation of Protein Release 
4.3.1 Background 
  
In many cases, designing a system with zero-order drug release kinetics is most 
desired. To meet this objective, numerous design variations have been proposed. For 
instance, Lee and Robinson et al. [121] have suggested several parameters for the 
drug release design. These parameters include the disease property, drug 
physicochemical and biological properties as well as design of drug delivery systems. 
The selection of polymers is critical to designing drug delivery systems. 
 
In our previous research, we have demonstrated that protein release from POE-
PEG(Mn 4,600)-POE microspheres was affected by many factors including polymer 
degradation rate, which largely depended on physicochemical properties of polymer 
such as molecular weight, hydrophilicity and compositions [122]. Processing 
conditions employed during the preparation of microspheres also influence protein 
release, which include particle size and morphology, protein encapsulation efficiency, 
as well as drug distribution [4]. In our research, experimental parameter changes 
could be an attractive approach to modify the microspheres properties as well as the 
release profiles of protein from microspheres [123, 124]. 
 
In this part, I focus on modulation of protein release by changing the molecular 
weight of PEG and POE composition. In the following paragraphs, BSA-loaded 
microspheres were fabricated using POE-PEG-POE with PEG having an average 
number molecular weight of 1,000 as well as POE-PEG-POE with a POE 
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composition of 1,2-PrD/1,2-PrD-diGL and CDM/TEG-diGL. Protein release from the 
microspheres was investigated.  
 
4.3.2 Effect of PEG Molecular Weight 
 
Although there are lots of studies on ABA (B: PEG) microspheres, few people have 
looked into the effect of PEG molecular weight. In my project, new POE-PEG-POE 
polymers with PEG having Mn of 1,000 were synthesized and utilized to fabricate 



























Figure 4.39 illustrates the average size of microspheres before and after the first day 
in vitro release. Due to the hydrophilicity of PEG, all the batches of POE-PEG (Mn 
1,000)-POE microspheres swelled after immersed in the buffer.  
  
Weight loss and molecular weight change of the POE-PEG (Mn 1,000)-POE 
microspheres were monitored paralleling to the in vitro study. The results are showed 
in Figures 4.40 and 4.41. The trends of weight loss and molecular weight change in 
Figure 4.39 Average mean diameter of POE-PEG (Mn 1,000)-POE 
microspheres before and after one-day in vitro. 
5%PEG 10%PEG 20%PEG
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POE-PEG(Mn 1,000)-POE microspheres were similar to those in POE-PEG (Mn 
4,600)-POE microspheres reported in Section 4.2. The POE-PEG (Mn 1,000)-POE 
microspheres with 5% and 10% PEG experienced a biphasic degradation pattern, 
characterized by a fast initial weight loss and a rapid decrease in molecular weight 
followed by a slow and constant loss in weight and molecular weight. However, the 
weight loss of POE-PEG (Mn 1,000)-POE microspheres with 20% PEG was more 
sustained, and its molecular weight was relatively constant. Changes in polydispersity 
index also followed a similar trend with an initial increase followed by a constant 
value (Figure 4.42) 
 
The results obtained from POE-PEG (Mn 1,000)-POE copolymers supported our 
previous hypothesis that POE-PEG-POE with 20% PEG possessed a better 
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Figure 4.40 Weight loss of POE-PEG (Mn 1,000)-POE microspheres 
as a function of incubation time.
Figure 4.41 Weight average molecular weight change of POE-PEG 
(Mn 1,000)-POE microspheres as a function of incubation time. 
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The release profiles of POE-PEG (Mn 1,000)-POE microspheres are shown in Figure 
4.43. Clearly, for POE-PEG (Mn 1,000)-POE microspheres, larger amount of BSA 
was released out compared to POE-PEG (Mn 4,600)-POE microspheres (Figure 4.30). 
Taking POE-PEG (5%)-POE as an example, the cumulative BSA release was about 
27% for PEG 4,600 while it increased to about 45% for PEG 1,000 microspheres. The 
possible reason is that POE-PEG (Mn 1,000)-POE microspheres had looser internal 
structure than the POE-PEG (Mn 4,600)-POE ones (Figure 4.44). 
Figure 4.42 Polydispersity index of POE-PEG (Mn 1,000)-POE 
microspheres with various PEG contents. 
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From Figure 4.43, it can also be observed that the microspheres made from POE-PEG 
(Mn 1,000)-POE with a PEG content of 20% provided a more sustained and linear 
BSA release profile compared to the copolymers with PEG contents of 5% and 10%. 
The linear and constant BSA release lasted 21 days, which is much longer than what 
POE-PEG (Mn 4,600)-POE microspheres provided. The cumulative BSA release 
could be enhanced when using 0.5 ml PVA/PBS (instead of 0.3 ml) as the internal 









Figure 4.43 Release profiles of POE-PEG (Mn 1,000)-POE microspheres in 
PBS, pH 7.4, 37°C. BSA loading is 10%. 









































Figure 4.44 Internal structure of (A) POE-PEG (Mn 1,000)-POE and (B) POE-
PEG (Mn 4,600)-POE microspheres. Sizes of the bars are10 µm and 5 µm, 
respectively. 
A                                                             B 
Figure 4.45 BSA release from POE-PEG (Mn 1,000)-POE microspheres 
with different internal water phases. 
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4.3.3 Effect of POE Compositions 
 
To achieve complete protein release from ABA (B: PEG) triblock copolymers, an 
alternative approach is to employing block A with less rigid structure or greater 
hydrophilicity such that water penetration could be faster. T. Kissel et al. reported that 
when the content of glycolic acid in PLGA blocks increased, the PLGA-PEG-PLGA 
microspheres yielded faster and more complete EPO and FITC-dextran release [7, 
119, 125].  
 
4.3.3.1 POE Composition: 1,2-PrD/1,2-PrD-diGL 
 
In this study, POE with a composition of 1,2-PrD/1,2-PrD-diGL was employed. PEG 
has an average number molecular weight of 1,000. Compared to CDM, 1,2-PrD is 
more flexible and hydrophilic. It was expected that water penetration rate through the 
polymer matrix would be higher. The properties of new POE-PEG-POE copolymers 
are listed in Table 4.10. 
 
The surface and internal morphology of resultant microspheres prepared from the new 
POE-PEG-POE copolymers were observed using SEM. The micrographs are shown 
in Figures 4.46 and 4.47. The porous surface was observed in the POE-PEG (1,000, 
5%)-POE microspheres (A, B and C). For POE-PEG (1,000, 20%)-POE microspheres 
(D, E and F) with the same composition, the surface was smoother. The porous 
surface for A, B and C microspheres might result from their lower molecular weight 
and inherent viscosity. In addition, the internal structure of A, B and C microspheres 
were more porous, and the D, E and F micropsheres with 20% PEG were relatively 
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dense. This phenomenon was also observed in the previous microspheres with the 
POE composition of CDM/TEG/TEG-diGL (94:5:1). 
 
 
Sample POE Composition 
(1,2-PrD:1,2-PrD-diGL) 
PEG % Inherent 
Viscosity (dL/g) 
Mw 
A 95:5 5 2.10 30553 
B 90:10 5 2.32 29877 
C 85:15 5 2.55 28086 
D 95:5 20 2.65 35031 
E 90:10 20 2.96 34138 
F 85:15 20 3.17 34283 
 
Figure 4.48 shows BSA encapsulation efficiency for all the copolymers. POE-PEG 
(Mn 1,000)-POE microspheres with 20% PEG yielded slightly higher encapsulation 
efficiency than those with 5% PEG. This is due to the more stable first emulsion 
(Figure 4.49) as well as stronger BSA-polymer affinity, preventing protein loss during 










Table 4.10 Properties of POE-PEG (Mn 1,000)-POE copolymers (POE: 
1,2-PrD/1,2-PrD-diGL) 






















Figure 4.46 Surface morphology of the A, B, C, D, E and F 













Figure 4.47 Internal structure of A, B, C, D, E and F 
microspheres. Size of the bars is 10 µm. 
E 
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Figure 4.49 Demixing time of the first emulsion of A to F polymers 
Figure 4.48 BSA encapsulation efficiency of A, B, C, D, E and F 
microspheres. 




























BSA release profiles from the microspheres are shown in Figure 4.50. Compared to 
POE-PEG (Mn 1,000)-POE microspheres with a POE composition of 
CDM/TEG/TEG-diGL (94/5/1), POE (1,2-PrD/1,2-PrD-diGL) yielded much faster 
BSA release. In addition, more BSA was released out from A, B and C microspheres. 
This mainly resulted from their porous structure. However, BSA release from D, E 
and F microspheres lasted for about 5 days. 
 
Figure 4.50 BSA release from the POE-PEG (Mn 1,000)-POE 
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4.3.3.2 POE Composition: CDM/TEG-diGL 
 
Another two copolymers based on PEG (Mn, 1,000) were synthesized with POE 
(CDM/TEG-diGL) containing different amount of TEG-diGL (Table 4.11), which 
were employed to investigate the effect of polymer composition on protein release. 
 
 
Sample POE composition PEG % Inherent 
Viscosity (dL/g) 
MW 
G CDM/TEG-diGL (95:5) 5 2.89 25856 
H CDM/TEG-diGL(85:15) 5 3.12 26445 
 
The CDM/TEG-diGL (85:15)-based polymer yielded much higher BSA encapsulation 
efficiency (80%) compared to the CDM/TEG-diGL (95:5)-based polymers (42%). It 
may be due to the slow solidification and unstable first emulsion. As we can see from 
Figure 4.51, big pores were observed in the G microspheres, resulting from the 
unstable first emulsion. However, the H microspheres had a uniform internal 
structure.   
 
 
Table 4.11 Properties of POE-PEG (5%, Mn 1,000)-POE copolymers (POE: 
CDM/TEG-diGL). 




G                                                    H 
Figure 4.51 Surface and internal morphology of G and H microspheres. Size of 
the bars is 10µm. 













BSA release from the H microspheres was sustained over 3 days, and much more 
BSA came out during the in vitro course compared to the G microspheres.  
 
Therefore, the composition of POE should be well-designed in order to achieve a 
desired protein release profile. 
Figure 4.52 BSA release from G and H microspheres. BSA 


































RESULTS AND DISCUSSION 2: 
 
POE/PEG BLEND MICROSPHERES 
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The use of polymer blends as drug carriers represents an appealing approach for 
controlled release applications. Blending of homopolymers presents a powerful 
alternative, which is superior in terms of simplicity and low cost compared to 
copolymerization. Various blends have been reported useful for drug delivery 
applications [126-128]. The stability, morphology, and performance of polymer 
blends are intimately connected to the polymer miscibility. Miscible polymers form 
blends with properties analogous to those of a single-phase material. Most polymer 
systems are however non-compatible resulting in non-uniformity or phase separation 
[129]. Depending on the thermodynamic compatibility of the two chosen polymers, 
phase-separated polymers can be obtained, imposing different morphologies and 
matrix characteristics and different drug release rates. Also, the degradation and 
release performance can be controlled through varying component ratios. It was 
reported that PLGA blended with PEG yielded better release profiles of proteins 
compared to neat PLGA [101] [103]. 
 
In this part, I focus on POE/PEG blend microspheres for protein delivery. The 
microspheres are fabricated by the double emulsion method. The objective of this 
study is to investigate the effect of polymer blends on particle size, surface 
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5.1 Microspheres Characterization 
5.1.1 Particle Size Distribution 
 
The average particle size of POE/PEG(MW 4,600), POE/PEG(MW 100,000) and 
POE/PEG(MW 200,000) blend microspheres immediately after fabrication is listed in 
Table 5.1, 5.2 and 5.3. For the POE/PEG (MW 4,600) blends, with the increasing of 
PEG content, particle size decreased because of the dissolution of PEG and less 
viscous polymer solution during the fabrication process. 10% PEG content yielded the 
biggest microspheres due to the highest inherent viscosity of polymer solution. For 
the POE/PEG (MW 100,000 and 200,000) blends, an increased PEG content also 
produced bigger microspheres although the polymer solution was more viscous at 
high PEG contents (Table 5.4a, 5.4b and 5.4c). This was probably because PEG loss 
in the external aqueous phase was a dominant factor. Interestingly, the diameter of 
blend microspheres was similar to that of the microspheres made from POE-PEG-
POE block copolymers. This was because their inherent viscosities of polymer 
solutions were very closed (Table 5.4a, Table 4.1).  
 
5.1.2 Thermal Properties 
 
The Tg values of blank microspheres are listed in Table 5.5a, 5.5b and 5.5c. POE 
blank microspheres exhibited a Tg of about 104 ºC and PEG (MW 4,600) polymer 
showed a Tm of 63 ºC, PEG (MW 100,000 and 200,000) with a slightly higher Tm 
which is around 65.5 ºC resulting from increased molecular weights. For all 
POE/PEG blend microspheres, down shifts in both Tg and Tm by 2-3 ºC and 1-3 ºC, 
respectively, were observed, indicating POE and PEG were partial miscible.  
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Table 5.4a Inherent viscosity of POE:PEG(Mn 4,600)/CH2Cl2 solution. 
Table 5.4b Inherent viscosity of POE:PEO(Mn100,000)/CH2Cl2 solution. 
3.77 80:20 
3.49 90:10 
7.76 PEO 100,000 
3.03 95:5 
Inherent viscosity (dL/g) Polymer blend (POE/PEG) ratio 
4.74 80:20 
3.59 90:10 
8.47 PEO 200,000 
3.05 95:5 
Inherent viscosity (dL/g) Polymer blend (POE/PEO) ratio 




1.61 PEG 4,600 
2.81 95:5 
Inherent viscosity (dL/g) Polymer blend (POE/PEG) ratio 
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5.1.3 PEG Contents in the Microspheres 
 
The fabrication process involved a large volume of water and lasted about 4 hours. 
PEG is water-soluble. How much PEG was left in the microspheres? The H1-NMR 
spectra of POE, PEG and POE/PEG blend microspheres are shown in Figures 5.1, 5.2 
and 5.3, from which the PEG contents were calculated and listed in Tables 5.6a-5.6c. 
Clearly, a substantial fraction of PEG was lost into the aqueous phase during the 
microspheres fabrication process. PEO content of POE/PEO (MW 100,000 and 
200,000) microspheres was much higher than that of POE/PEG (MW 4,600) blend 
microspheres. This is because the water-solubility of PEG with high molecular 
weights is lower, leading to more PEG incorporated in the microspheres. Increasing 
initial PEG loading yielded microspheres with higher PEG contents. PEG content 
would have a significant effect on BSA release. As reported, the presence of PEG can 
prevent the formation of BSA aggregates. On the other hand, during the course of in 
vitro release, the dissolution of PEG would leave pores and channels for the ease of 
BSA diffusion. 
 

































Figure 5.1 H1-NMR of: A, POE polymer; B, PEG (MW 4,600) polymer; C, 
POE microspheres; D, E, F and G, POE/PEG (MW 4,600) blend microspheres 
with PEG weight percentage 5%, 10%, 20% and 30% respectively. 
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Figure 5.2 NMR of: A, POE microspheres; B: PEO (MW 100,000) 
polymer; C, D, E: POE/PEO (MW 100,000) blend microspheres with PEO 
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Figure 5.3 NMR of: A, POE microspheres; B, PEO (MW 200,000) 
polymer; C, D, E, POE/PEO (MW 200,000) blend microspheres with 
PEO weight percentage 5%, 10% and 20% respectively. 
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Table 5.6a Percentage of PEG(MW 4,600) incorporated in microspheres 
 
Initial PEG weight percentage, 
% 






Table 5.6b Percentage of PEO(MW 100,000) incorporated in microspheres. 
 
Initial PEG weight percentage, 
wt% 








Table 5.6c Percentage of PEG(MW 200,000) incorporated in microspheres. 
 
Initial PEG weight percentage, 
wt% 
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5.2 Microspheres Morphology 
5.2.1 Surface Morphology and Internal Structure of POE/PEG (MW 
4,600) Blend Microspheres 
 
POE/PEG(MW 4,600) blends yielded spherical particles with smooth surface when 
PEG weight percentage ranged from 5 to 20% (Figure 5.4). However, the surface of 
microspheres was rougher when 30% PEG was used. It was due to the loss of PEG 
into the external aqueous phase during the fabrication process. The internal structure 
of POE/PEG (MW 4,600) blend microspheres was shown in Figure 5.5. As reported 
in Chapter 4, the neat POE microspheres had a multi-vascular internal structure. 
However, POE/PEG blend microspheres with 5% PEG (MW 4,600) had more pores. 
When PEG content increased to 10%, the pores became smaller and more uniformly 
distributed. In addition, the inter-connection of pores was enhanced. In sharp contrast, 
macro-voids were observed within the micropsheres when PEG content further 
increased to 20% and 30%.  
 
The internal structure of microspheres was basically attributed to the stability of the 
first emulsion. Figure 5.6 shows the demixing time of the first emulsion with various 
contents of PEG. With the introduction of PEG, the first emulsion became more 
stable, yielding smaller and uniformly-distributed pores within the microspheres. 
When PEG content was 20% or 30%, the demixing time was even longer. The first 
emulsion should be more stable. However, when the first emulsion was injected into 
the external aqueous phase, due to the hydrophilic nature of PEG, more water could 
be introduced into the system with a higher PEG content, leading to phase separation 
between polymer/solvent/non- 
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solvent. Although a larger PEG content provided a more stable primary emulsion, 
greater water in-flux might result in the coalescence of internal water droplets during 
the fabrication process. Thus, macro-voids were observed within the microspheres 
























Moreover, it was observed that the microspheres made from POE/PEG (MW 4,600) 
had a dense wall. It is probably because the introduction of PEG led to rapid solvent 
removal during the fabrication process. Theoretically, there are many parameters 
which can affect the solvent removal: polymer molecular weight and concentration, 
polymer crystallization, drug nature and method of incorporation (solid, liquid or 
suspension), organic solvent used, surfactant, fabrication temperature and stirring 
speed. In the present study, polymer molecular weight as well as blend ratio might be 
the key factor. It can be inferred that the formation of dense walls might affect BSA 
release. 
Figure 5.6 Demixing time for first emulsion of POE/PEG(Mn 4,600) 
blend with various PEG content. 
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5.2.2 Water Uptake 
 
Water uptake is also an important parameter affecting polymer erosion and protein 
release. Figure 5.7 shows water absorption of the POE/PEG (MW 4,600) blend 
microspheres versus PEG content in PBS buffer (pH 7.4) at 37 ºC. The microspheres 
made with higher PEG contents had greater water uptake because of more porous 
structures created and the hydrophilic nature of PEG. It was also observed that it took 
about 7 days to reach the equilibrium of water absorption, which may be due to the 

























Figure 5.7 Water uptake of POE/PEG(MW 4,600) blend microspheres after 7 days 
in vitro. 
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5.2.3 Surface Morphology And Internal Structure of POE/PEO (MW 
100,000 and 200,000) Blend Microspheres 
 
Figures 5.8 and 5.9 show the surface morphologies of POE/PEO (MW 100,000 and 
200,000) blend microspheres. With the increasing of PEO content, their surfaces 
appeared to be rougher and more porous. Possibly, it resulted from the dissolution of 
hydrophilic PEO. As we expected, during the fabrication process, PEO tended to 
dissolve in the external aqueous phase and leave pores. An increased PEG content 
produced rougher and more porous microspheres.  
 
Figure 5.10 shows the internal structures of the microspheres. Interestingly, very 
porous internal structures were formed for the POE/PEG (MW 100,000) blend 
microspheres with various PEG contents. Except for POE/PEO(MW 100,000) 
microspheres with 5% PEG, where the pores size varied and the pores were separated, 
the microspheres with 10% or 20% PEG had a well inter-connected structure. Macro-
voids were not observed even at high PEG contents. The phase separation did not 
occurred because the PEGs with higher molecular weights had lower water-solubility. 
The water content within the first emulsion droplets was not high enough to induce 
phase separation. The water uptake for POE/PEO (MW 100,000 and 200,000) blend 
microspheres is shown in Figure 5.11. Lower water uptake of the microspheres with 
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Figure 5.11 Water uptake of POE/PEO(MW 100,000 and 200,000) blend 
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5.3 BSA Encapsulation Efficiency 




Figure 5.12 illustrates BSA encapsulation efficiency of the POE/PEG (MW 4,600) 
blend microspheres with various PEG contents. From the figure, it can be observed 
that in the range from 0% to 10%, an increased PEG content led to increased BSA 
encapsulation efficiency. However, further increasing PEG content to 20%, the 
encapsulation efficiency dropped tremendously. For instance, 10% PEG yielded the 
highest encapsulation efficiency (70%), whereas it decreased to 30% at a PEG content 
of 20%.  
 
M. K. Yeh et al. reported the protein loading efficiency was improved with the 
blending of PLGA with PEG compared to the microspheres made from PLGA alone 
[94]. However there were also results that described negative or insignificant effect of 



















Figure 5.12 Encapsulation efficiency of POE/PEG(MW 4,600) blend 
microspheres. 
                                                                                          Chapter 5   Results and Discussions 2 
 166
emulsion provided by the addition of PEG might account for the increased 
encapsulation efficiency of BSA. However, at high PEG contents (20 and 30%), 
greater water flux allowed more BSA to migrate towards the external aqueous phase, 
leading to lower encapsulation efficiency. On the other hand, the dissolution of more 
PEG could promote the loss of proteins. Furthermore, since a substantial amount of 
PEG was lost during the fabrication process, the overall polymer concentration was 
lower when higher contents of PEG were employed. Lower polymer concentration 
generally resulted in reduced encapsulation efficiency. 
 















































Figure 5.13 shows BSA encapsulation efficiency of the microspheres made from 
POE/PEG (MW 100,000 and 200,000) blends. Similarly, an increased PEG content 
led to decreased encapsulation efficiency. Compared to POE/PEG (MW 100,000) 
Figure 5.13 Encapsulation efficiency of POE/PEO(MW 100,000 and 
200,000) blend microspheres. 
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blend microspheres, BSA encapsulation efficiency of POE/PEO (200,000) blend 
microspheres was more dependent on PEG content.  
 
5.4 BSA Release Profiles 




Figure 5.14 shows BSA release profiles from the POE/PEG blend microspheres. The 
release profiles were characterized by a lag phase followed by a sustained release of 
BSA. The dense wall surrounding the microspheres and hydrophobic nature of POE 
accounted for the existence of lag phase. The second phase (the sustained release 
phase) was due to BSA diffusion through the pores and polymer erosion. The 
introduction of PEG shortened the lag phase of BSA release, and achieved faster BSA 
release as well as more BSA released during the course of in vitro tests. The inter-
connected porous structures enabled BSA to diffuse more easily. In addition, PEG 


















0 5% 10% 20% 30%
Figure 5.14 BSA release profiles of POE/PEG(MW 4,600) blend 
microspheres. BSA loading is 10%. 
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Smaller particle size could be another reason. These results were consistent with what 
reported by M. K. Yeh et al. [94] and M. Wei et al. [127]. Interestingly, 5 and 10% 
PEG yielded a more sustained BSA release probably due to the more regularly 
distributed internal porous structure. 
 


























Figure 5.15 BSA release profiles of POE/PEG (MW 100,000 and 200,000) blend 
microspheres. BSA loading is 10%. 
 
Release profiles of POE/PEG (MW 100,000 and 200,000) blend microspheres 
followed a very interesting pattern (Figure 5.15). It was largely determined by the 
particle size and internal structures. 
 
A lag phase was still observed for the POE/PEO (MW 100,000 and 200,000) blend 
microspheres with 5% or 10% PEG. However, BSA release from the microspheres 
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made with 20% PEG (MW 200,000) was sustained over 3 weeks without lag phase. 
This is probably because the small particles (Table 5.2) provided greater surface area 
for BSA diffusion and dissolution.  
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6.1 POE-PEG-POE Microspheres 
 
POE-PEG-POE with different molecular weights of PEG and various PEG contents 
have been employed to encapsulate protein using an improved W/O/W double 
emulsion evaporation/extraction method. This research work has demonstrated that 
spherical microparticles could be produced with POE-PEG-POE triblock copolymers 
having PEG contents of 5%, 10% and 20%. The protein distribution within the 
microspheres was uniform. Attaching a PEG block to POE polymer backbone yielded 
a more stable first emulsion (W/O) and thus a higher BSA encapsulation efficiency. 
However, PEG content and preparation conditions such as BSA loading, polymer 
concentration, PVA concentration in the external aqueous phase did not have 
significant influence on BSA encapsulation efficiency due to the stable first emulsion. 
Microsphere size could be tailored by the variation of polymer concentration. The 
absence of salt in the external aqueous phase yielded slightly higher encapsulation 
efficiency resulting from tighter and denser microsphere skins formed during the 
fabrication process.  
 
Degradation of POE-PEG(5%)-POE and POE-PEG(10%)-POE triblock copolymers 
was characterised by an initial decrease in molecular weight and increase in 
polydispersity index during the first 2 weeks, which is followed by a constant value 
over 12 weeks in vitro while 90% mass was lost. However, POE-PEG(20%)-POE 
might possess a better compatibility between the POE and PEG blocks resulting in a 
relatively constant polydispersity index and molecular weight as well as a sustained 
weight loss. During the in vitro degradation, surface and internal morphologies of the 
microspheres did not change significantly. The microspheres eroded possibly from 
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their surfaces. The triblock copolymers with lower PEG contents did not show 
swelling but the POE-PEG(20%)-POE microspheres swells significantly after 
immersed in PBS buffer. Swelling of the microsphere matrices promoted release of 
the encapsulated proteins and leads to more complete proteins released. Protein 
release from the triblock copolymeric microspheres showed a biphasic pattern at low 
loading levels. The initial phase was dominated by diffusion and erosion for POE-
PEG(5%)-POE and POE-PEG(10%)-POE. But for POE-PEG(20%)-POE, it depended 
on swelling, diffusion and erosion. The second phase might be controlled by 
properties of POE blocks and dense matrix structures. Intact BSA could remain 
within the matrices for 8 weeks in PBS buffer at pH 7.4, 37°C. A sustained protein 
release from POE-PEG(20%)-POE microspheres was achieved over two weeks at a 
high protein loading level.  
 
PEG molecular weight did not have significant effect on release properties of BSA-
loaded POE-PEG-POE microspheres. BSA release was much faster from POE-PEG-
POE triblock copolymers with a POE composition of 1,2-PrD/1,2-PrD-diGL 
compared to the copolymers with a POE composition of CDM/TEG/TEG-diGL since 
1,2-PrD is more flexible and hydrophilic. Therefore, the composition of POE should 
be well designed to yield a sustained and linear protein release. 
 
6.2 POE/PEG Blend Microspheres 
 
We fabricated microspheres from poly(ortho esters) (POE) and poly(ethylene glycol) 
(PEG) blends, BSA was entrapped using a double emulsion solvent 
extraction/evaporation technology to investigate the effect of blend ratio and PEG 
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molecular weight on microspheres property and release kinetics. NMR and DSC 
studies showed that a certain amount of PEG still remained in microspheres even after 
several hours’ microspheres fabrication process. The remained PEG content in 
microspheres depended on the POE/PEG initial blend ratio as well as their molecular 
weights. The higher the PEG molecular weight, the more PEG remained in 
microspheres. DSC test revealed POE and PEG had partial miscibility. Swelling was 
observed for all the blend microspheres. Water uptake increased with the increasing 
of PEG content. All the blend microspheres had porous internal structure. It has also 
been observed that when the PEG(MW 4,600) content was as high as 20% and 30%, 
microcapsules could be formed. Definitely, the microcapsule internal structure would 
influence the protein release. These results demonstrate the feasibility of modulating 
the release profile of entrapped protein in biodegradable microspheres by adjusting 
the POE/PEG blend ratio and PEG molecular weight. 
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